基本信息

产品名称	Recombinant CYP2D6 Antibody
别名	细胞色素P450 2D6重组兔单克隆抗体 \| 细胞色素P450 2D6重组兔单克隆抗体
英文别名	Cholesterol 25-hydroxylase antibody \| CP2D6_HUMAN antibody \| CPD6 antibody \| CYP2D antibody \| CYP2D6 antibody \| CYP2D7AP antibody \| CYP2D7BP antibody \| CYP2D7P2 antibody \| CYP2D8P2 antibody \| CYP2DL1 antibody \| CYPIID6 antibody \| Cytochrome P450 2D6 antib
规格或纯度	重组, ExactAb™, 已验证, 0.5 mg/mL
生化机理	Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
宿主种属	兔(Rabbit)
特异性	CYP2D6
种属反应性	人(Human),大鼠(Rat),小鼠(Mouse)
免疫原	Recombinant protein of human CYP2D6.
阳性对照	WB: Mouse liver, Rat liver lysates. IHC: Human liver cancer tissue. IF/ICC: HeLa cells.
偶联	Unconjugated

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Rabbit IgG
纯化方法	Immunogen affinity purified
物理外观	Liquid
储存缓冲液	50mM Tris-Glycine, 150mM NaCl, 50% Glycerol, 0.05% BSA, 0.01% Sodium azide, pH 7.4
防腐剂	0.01% Sodium azide
浓度	0.5 mg/mL
储存温度	-20°C储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	4℃ 短期储存（1-2 周）。-20℃长期保存（24 个月）。收货后建议分装。避免冷冻/解冻循环。
分子类型	抗体

关联靶点（人）

CYP2D6 Tclin 细胞色素 P450 2D6(Cytochrome P450 2D6) (0 活性数据)

点击查看靶蛋白信息： CYP2D6

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Western Blot: Recombinant CYP2D6 Antibody (Ab098589)

Recombinant CYP2D6 Antibody (Ab098589) - Western Blot
All lanes: Recombinant CYP2D6 Antibody (Ab098589) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/40000 dilution
Predicted band size: 56 kDa
Observed band size: 48 kDa
Exposure time: 3.1 s

IHC: Recombinant CYP2D6 Antibody (Ab098589)

Recombinant CYP2D6 Antibody (Ab098589) - IHC
Immunohistochemical analysis of Cytochrome P450 2D6 staining in human liver cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with Recombinant CYP2D6 Antibody (Ab098589) at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

IF/ICC: Recombinant CYP2D6 Antibody (Ab098589)

Recombinant CYP2D6 Antibody (Ab098589) - IF/ICC
Immunofluorescent analysis of Cytochrome P450 2D6 staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with Recombinant CYP2D6 Antibody (Ab098589) in 3% BSA-PBS and incubated overnight at 4 °C in a hidified chamber. Cells were washed with PBST and incubated with a AF488-conjugated secondary antibody (green) in PBS at room temperature in the dark.

应用

应用名称	稀释比例
WB	1/500-1/1000
IHC	1/50 - 1/100
IF/ICC	1/50-1/100

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到2个结果

批号(Lot Number)	证书类型	货号
ZJ25F0117360	分析证书	Ab098589
ZJ25F0117359	分析证书	Ab098589

引用文献

1. Song F, Lu S, Gunnet J, Xu JZ, Wines P, Proost J, Liang Y, Baumann C, Lenhard J, Murray WV et al.. (2007) Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.. J Med Chem, 50 (12): (2807-17). [PMID:17500511]
2. Thoma G, Streiff MB, Kovarik J, Glickman F, Wagner T, Beerli C, Zerwes HG. (2008) Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.. J Med Chem, 51 (24): (7915-20). [PMID:19053768]
3. Ahmad S, Madsen CS, Stein PD, Janovitz E, Huang C, Ngu K, Bisaha S, Kennedy LJ, Chen BC, Zhao R et al.. (2008) (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.. J Med Chem, 51 (9): (2722-33). [PMID:18412317]
4. Bolli MH, Marfurt J, Grisostomi C, Boss C, Binkert C, Hess P, Treiber A, Thorin E, Morrison K, Buchmann S et al.. (2004) Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.. J Med Chem, 47 (11): (2776-95). [PMID:15139756]
5. Xia Y, Chackalamannil S, Greenlee WJ, Jayne C, Neustadt B, Stamford A, Vaccaro H, Xu XL, Baker H, O'Neill K et al.. (2011) Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.. Bioorg Med Chem Lett, 21 (11): (3290-6). [PMID:21536438]
6. Scott JS, Birch AM, Brocklehurst KJ, Broo A, Brown HS, Butlin RJ, Clarke DS, Davidsson O, Ertan A, Goldberg K et al.. (2012) Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.. J Med Chem, 55 (11): (5361-79). [PMID:22545772]
7. Morley AD, King S, Roberts B, Lever S, Teobald B, Fisher A, Cook T, Parker B, Wenlock M, Phillips C et al.. (2012) Lead optimisation of pyrazoles as novel FPR1 antagonists.. Bioorg Med Chem Lett, 22 (1): (532-6). [PMID:22094028]
8. Boatman PD, Lauring B, Schrader TO, Kasem M, Johnson BR, Skinner P, Jung JK, Xu J, Cherrier MC, Webb PJ et al.. (2012) (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans.. J Med Chem, 55 (8): (3644-66). [PMID:22435740]
9. Shen HC, Ding FX, Raghavan S, Deng Q, Luell S, Forrest MJ, Carballo-Jane E, Wilsie LC, Krsmanovic ML, Taggart AK et al.. (2010) Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.. J Med Chem, 53 (6): (2666-70). [PMID:20184326]
10. McHardy T, Caldwell JJ, Cheung KM, Hunter LJ, Taylor K, Rowlands M, Ruddle R, Henley A, de Haven Brandon A, Valenti M et al.. (2010) Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).. J Med Chem, 53 (5): (2239-49). [PMID:20151677]
11. Rudolph J, Esler WP, O'connor S, Coish PD, Wickens PL, Brands M, Bierer DE, Bloomquist BT, Bondar G, Chen L et al.. (2007) Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity.. J Med Chem, 50 (21): (5202-16). [PMID:17887659]
12. Sheffler DJ, Wenthur CJ, Bruner JA, Carrington SJ, Vinson PN, Gogi KK, Blobaum AL, Morrison RD, Vamos M, Cosford ND et al.. (2012) Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM.. Bioorg Med Chem Lett, 22 (12): (3921-5). [PMID:22607673]
13. Jones CK, Engers DW, Thompson AD, Field JR, Blobaum AL, Lindsley SR, Zhou Y, Gogliotti RD, Jadhav S, Zamorano R et al.. (2011) Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.. J Med Chem, 54 (21): (7639-47). [PMID:21966889]
14. Duplantier AJ, Efremov I, Candler J, Doran AC, Ganong AH, Haas JA, Hanks AN, Kraus KG, Lazzaro Jr JT, Lu J et al.. (2009) 3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization.. Bioorg Med Chem Lett, 19 (9): (2524-9). [PMID:19328692]
15. Cid JM, Duvey G, Tresadern G, Nhem V, Furnari R, Cluzeau P, Vega JA, de Lucas AI, Matesanz E, Alonso JM et al.. (2012) Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor.. J Med Chem, 55 (5): (2388-405). [PMID:22364337]
16. Christiansen E, Hansen SV, Urban C, Hudson BD, Wargent ET, Grundmann M, Jenkins L, Zaibi M, Stocker CJ, Ullrich S et al.. (2013) Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes.. ACS Med Chem Lett, 4 (5): (441-445). [PMID:23687558]
17. Cui JJ, McTigue M, Nambu M, Tran-Dubé M, Pairish M, Shen H, Jia L, Cheng H, Hoffman J, Le P et al.. (2012) Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.. J Med Chem, 55 (18): (8091-109). [PMID:22924734]
18. Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, Doty JL, Elliott EA, Fisher MB, Hines M et al.. (2010) Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.. J Med Chem, 53 (24): (8468-84). [PMID:21105711]
19. Hilpert H, Guba W, Woltering TJ, Wostl W, Pinard E, Mauser H, Mayweg AV, Rogers-Evans M, Humm R, Krummenacher D et al.. (2013) β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.. J Med Chem, 56 (10): (3980-95). [PMID:23590342]
20. Evans KA, Budzik BW, Ross SA, Wisnoski DD, Jin J, Rivero RA, Vimal M, Szewczyk GR, Jayawickreme C, Moncol DL et al.. (2009) Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists.. J Med Chem, 52 (24): (7962-5). [PMID:19902954]
21. Nagase T, Mizutani T, Ishikawa S, Sekino E, Sasaki T, Fujimura T, Ito S, Mitobe Y, Miyamoto Y, Yoshimoto R et al.. (2008) Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.. J Med Chem, 51 (15): (4780-9). [PMID:18598020]
22. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A et al.. (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.. J Med Chem, 54 (9): (3206-21). [PMID:21486038]
23. Huynh T, Chen Z, Pang S, Geng J, Bandiera T, Bindi S, Vianello P, Roletto F, Thieffine S, Galvani A et al.. (2009) Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).. Bioorg Med Chem Lett, 19 (11): (2924-7). [PMID:19419866]
24. Pinard E, Alanine A, Alberati D, Bender M, Borroni E, Bourdeaux P, Brom V, Burner S, Fischer H, Hainzl D et al.. (2010) Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.. J Med Chem, 53 (12): (4603-14). [PMID:20491477]
25. Cumming JG, Tucker H, Oldfield J, Fielding C, Highton A, Faull A, Wild M, Brown D, Wells S, Shaw J. (2012) Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 22 (4): (1655-9). [PMID:22266038]
26. Scott JS, Bowker SS, Deschoolmeester J, Gerhardt S, Hargreaves D, Kilgour E, Lloyd A, Mayers RM, McCoull W, Newcombe NJ et al.. (2012) Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).. J Med Chem, 55 (12): (5951-64). [PMID:22691057]
27. William AD, Lee AC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Tan E, Chen D, Williams M, Sun ET et al.. (2011) Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.. J Med Chem, 54 (13): (4638-58). [PMID:21604762]
28. Birch AM, Birtles S, Buckett LK, Kemmitt PD, Smith GJ, Smith TJ, Turnbull AV, Wang SJ. (2009) Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor.. J Med Chem, 52 (6): (1558-68). [PMID:19256504]
29. Aston NM, Bamborough P, Buckton JB, Edwards CD, Holmes DS, Jones KL, Patel VK, Smee PA, Somers DO, Vitulli G et al.. (2009) p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.. J Med Chem, 52 (20): (6257-69). [PMID:19772287]
30. Liu C, Lin J, Wrobleski ST, Lin S, Hynes J, Wu H, Dyckman AJ, Li T, Wityak J, Gillooly KM et al.. (2010) Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.. J Med Chem, 53 (18): (6629-39). [PMID:20804198]
31. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H et al.. (2011) Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.. J Med Chem, 54 (20): (7066-83). [PMID:21936542]
32. Burger MT, Pecchi S, Wagman A, Ni ZJ, Knapp M, Hendrickson T, Atallah G, Pfister K, Zhang Y, Bartulis S et al.. (2011) Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.. ACS Med Chem Lett, 2 (10): (774-9). [PMID:24900266]
33. Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L et al.. (2012) Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.. J Med Chem, 55 (3): (1082-105). [PMID:22168626]
34. Currie KS, Kropf JE, Lee T, Blomgren P, Xu J, Zhao Z, Gallion S, Whitney JA, Maclin D, Lansdon EB et al.. (2014) Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.. J Med Chem, 57 (9): (3856-73). [PMID:24779514]
35. Sampson PB, Liu Y, Patel NK, Feher M, Forrest B, Li SW, Edwards L, Laufer R, Lang Y, Ban F et al.. (2015) The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.. J Med Chem, 58 (1): (130-46). [PMID:24867403]
36. Hanan EJ, van Abbema A, Barrett K, Blair WS, Blaney J, Chang C, Eigenbrot C, Flynn S, Gibbons P, Hurley CA et al.. (2012) Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.. J Med Chem, 55 (22): (10090-107). [PMID:23061660]
37. Goodfellow VS, Loweth CJ, Ravula SB, Wiemann T, Nguyen T, Xu Y, Todd DE, Sheppard D, Pollack S, Polesskaya O et al.. (2013) Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.. J Med Chem, 56 (20): (8032-48). [PMID:24044867]
38. Millan DS, Bunnage ME, Burrows JL, Butcher KJ, Dodd PG, Evans TJ, Fairman DA, Hughes SJ, Kilty IC, Lemaitre A et al.. (2011) Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.. J Med Chem, 54 (22): (7797-814). [PMID:21888439]
39. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K et al.. (2012) Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.. J Med Chem, 55 (2): (903-13). [PMID:22148921]
40. Fang X, Yin Y, Chen YT, Yao L, Wang B, Cameron MD, Lin L, Khan S, Ruiz C, Schröter T et al.. (2010) Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.. J Med Chem, 53 (15): (5727-37). [PMID:20684608]
41. Pan Y, Gerasimov MR, Kvist T, Wellendorph P, Madsen KK, Pera E, Lee H, Schousboe A, Chebib M, Bräuner-Osborne H et al.. (2012) (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction.. J Med Chem, 55 (1): (357-66). [PMID:22128851]
42. Yin L, Hu Q, Emmerich J, Lo MM, Metzger E, Ali A, Hartmann RW. (2014) Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.. J Med Chem, 57 (12): (5179-89). [PMID:24899257]
43. Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA et al.. (2010) Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.. J Med Chem, 53 (10): (3973-4001). [PMID:20420387]
44. Foote KM, Blades K, Cronin A, Fillery S, Guichard SS, Hassall L, Hickson I, Jacq X, Jewsbury PJ, McGuire TM et al.. (2013) Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.. J Med Chem, 56 (5): (2125-38). [PMID:23394205]
45. De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J et al.. (2011) Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.. Bioorg Med Chem Lett, 21 (11): (3301-6). [PMID:21536437]
46. Wenthur CJ, Morrison R, Felts AS, Smith KA, Engers JL, Byers FW, Daniels JS, Emmitte KA, Conn PJ, Lindsley CW. (2013) Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM).. J Med Chem, 56 (12): (5208-12). [PMID:23718281]
47. Vachal P, Miao S, Pierce JM, Guiadeen D, Colandrea VJ, Wyvratt MJ, Salowe SP, Sonatore LM, Milligan JA, Hajdu R et al.. (2012) 1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.. J Med Chem, 55 (7): (2945-59). [PMID:22364528]
48. Griffith DA, Dow RL, Huard K, Edmonds DJ, Bagley SW, Polivkova J, Zeng D, Garcia-Irizarry CN, Southers JA, Esler W et al.. (2013) Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure.. J Med Chem, 56 (17): (7110-9). [PMID:23981033]
49. Sandham DA, Arnold N, Aschauer H, Bala K, Barker L, Brown L, Brown Z, Budd D, Cox B, Docx C et al.. (2013) Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.. Bioorg Med Chem, 21 (21): (6582-91). [PMID:24021582]
50. Duplantier AJ, Dombroski MA, Subramanyam C, Beaulieu AM, Chang SP, Gabel CA, Jordan C, Kalgutkar AS, Kraus KG, Labasi JM et al.. (2011) Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.. Bioorg Med Chem Lett, 21 (12): (3708-11). [PMID:21565499]
51. William AD, Lee AC, Goh KC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Lee CP, Wang H, Williams M et al.. (2012) Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer.. J Med Chem, 55 (1): (169-96). [PMID:22148278]
52. Xiong Y, Guo J, Candelore MR, Liang R, Miller C, Dallas-Yang Q, Jiang G, McCann PE, Qureshi SA, Tong X et al.. (2012) Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.. J Med Chem, 55 (13): (6137-48). [PMID:22708876]
53. Reeves EK, Hoffman EP, Nagaraju K, Damsker JM, McCall JM. (2013) VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.. Bioorg Med Chem, 21 (8): (2241-9). [PMID:23498916]
54. Kamenecka T, Jiang R, Song X, Duckett D, Chen W, Ling YY, Habel J, Laughlin JD, Chambers J, Figuera-Losada M et al.. (2010) Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.. J Med Chem, 53 (1): (419-31). [PMID:19947601]
55. Savall BM, Chavez F, Tays K, Dunford PJ, Cowden JM, Hack MD, Wolin RL, Thurmond RL, Edwards JP. (2014) Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H₄ receptor antagonists.. J Med Chem, 57 (6): (2429-39). [PMID:24495018]
56. Goldstein DM, Soth M, Gabriel T, Dewdney N, Kuglstatter A, Arzeno H, Chen J, Bingenheimer W, Dalrymple SA, Dunn J et al.. (2011) Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.. J Med Chem, 54 (7): (2255-65). [PMID:21375264]
57. Gaggini F, Laleu B, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F et al.. (2011) Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors.. Bioorg Med Chem, 19 (23): (6989-99). [PMID:22041175]
58. Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F et al.. (2010) First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.. J Med Chem, 53 (21): (7715-30). [PMID:20942471]
59. Moore WJ, Kern JC, Bhat R, Commons TJ, Fukayama S, Goljer I, Krishnamurthy G, Magolda RL, Nogle L, Pitts K et al.. (2009) Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides.. J Med Chem, 52 (1): (105-16). [PMID:19072540]
60. Fretz H, Valdenaire A, Pothier J, Hilpert K, Gnerre C, Peter O, Leroy X, Riederer MA. (2013) Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.. J Med Chem, 56 (12): (4899-911). [PMID:23721423]
61. Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, Wen D, Long H, Luo J, Feng Y et al.. (2013) Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.. J Med Chem, 56 (3): (879-94). [PMID:23301703]
62. Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, Kostich W, Lentz KA, Santone KS, Schartman R et al.. (2012) Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine.. J Med Chem, 55 (23): (10644-51). [PMID:23153230]
63. Chaturvedula PV, Mercer SE, Pin SS, Thalody G, Xu C, Conway CM, Keavy D, Signor L, Cantor GH, Mathias N et al.. (2013) Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.. Bioorg Med Chem Lett, 23 (11): (3157-61). [PMID:23632269]
64. Makoto Matsumoto,Hiroyuki Hashizume,Tatsuo Tomishige,Masanori Kawasaki,Hidetsugu Tsubouchi,Hirofumi Sasaki,Yoshihiko Shimokawa,Makoto Komatsu. (2006-11-30) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.. PLoS medicine, 3 ((11)): (e466-e466). [PMID:17132069]
65. Derek C Cole,Joseph R Stock,Anthony F Kreft,Madelene Antane,Suzan H Aschmies,Kevin P Atchison,David S Casebier,Thomas A Comery,George Diamantidis,John W Ellingboe,Boyd L Harrison,Yun Hu,Mei Jin,Dennis M Kubrak,Peimin Lu,Charles W Mann,Robert L Martone,William J Moore,Aram Oganesian,David R Riddell,June Sonnenberg-Reines,Shaiu-Ching Sun,Erik Wagner,Zheng Wang,Kevin R Woller,Zheng Xu,Hua Zhou,J Steven Jacobsen. (2008-12-23) (S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor.. Bioorganic & medicinal chemistry letters, 19 ((3)): (926-929). [PMID:19097890]
66. Stuart N L Bennett,Andrew D Campbell,Andrew Hancock,Craig Johnstone,Peter W Kenny,Adrian Pickup,Alleyn T Plowright,Nidhal Selmi,Iain Simpson,Andy Stocker,David P Whalley,Paul R O Whittamore. (2010-05-25) Discovery of a series of indan carboxylic acid glycogen phosphorylase inhibitors.. Bioorganic & medicinal chemistry letters, 20 ((12)): (3511-3514). [PMID:20493691]
67. Jill M Scott,Christopher Baccei,Gretchen Bain,Alex Broadhead,Jilly F Evans,Patrick Fagan,John H Hutchinson,Christopher King,Daniel S Lorrain,Catherine Lee,Peppi Prasit,Pat Prodanovich,Angelina Santini,Brian A Stearns. (2011-10-01) Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.. Bioorganic & medicinal chemistry letters, 21 ((21)): (6608-6612). [PMID:21958540]
68. Weiguo Liu,Fiona Lau,Kun Liu,Harold B Wood,Gaochao Zhou,Yuli Chen,Ying Li,Taro E Akiyama,Gino Castriota,Monica Einstein,Chualin Wang,Margaret E McCann,Thomas W Doebber,Margaret Wu,Ching H Chang,Lesley McNamara,Brian McKeever,Ralph T Mosley,Joel P Berger,Peter T Meinke. (2011-11-11) Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.. Journal of medicinal chemistry, 54 ((24)): (8541-8554). [PMID:22070604]
69. Guan-Sheng Jiao,Seongjin Kim,Mahtab Moayeri,Devorah Crown,April Thai,Lynne Cregar-Hernandez,Linda McKasson,Banumathi Sankaran,Axel Lehrer,Teri Wong,Lisa Johns,Stephen A Margosiak,Stephen H Leppla,Alan T Johnson. (2012-02-22) Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.. Bioorganic & medicinal chemistry letters, 22 ((6)): (2242-2246). [PMID:22342144]
70. Raman Sharma,Hao Sun,David W Piotrowski,Tim F Ryder,Shawn D Doran,Haiqing Dai,Chandra Prakash. (2012-08-17) Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.. Drug metabolism and disposition: the biological fate of chemicals, 40 ((11)): (2143-2161). [PMID:22896728]
71. James S Scott,Joanne deSchoolmeester,Elaine Kilgour,Rachel M Mayers,Martin J Packer,David Hargreaves,Stefan Gerhardt,Derek J Ogg,Amanda Rees,Nidhal Selmi,Andrew Stocker,John G Swales,Paul R O Whittamore. (2012-10-24) Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: the discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329).. Journal of medicinal chemistry, 55 ((22)): (10136-10147). [PMID:23088558]
72. Pasha M Khan,Bahaa El-Dien M El-Gendy,Naresh Kumar,Ruben Garcia-Ordonez,Li Lin,Claudia H Ruiz,Michael D Cameron,Patrick R Griffin,Theodore M Kamenecka. (2012-12-13) Small molecule amides as potent ROR-γ selective modulators.. Bioorganic & medicinal chemistry letters, 23 ((2)): (532-536). [PMID:23232056]
73. Zaihui Zhang,Shaoyi Sun,Vishnumurthy Kodumuru,Duanjie Hou,Shifeng Liu,Nagasree Chakka,Serguei Sviridov,Sultan Chowdhury,David G McLaren,Leslie G Ratkay,Kuldip Khakh,Xing Cheng,Heinz W Gschwend,Rajender Kamboj,Jianmin Fu,Michael D Winther. (2012-12-19) Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.. Journal of medicinal chemistry, 56 ((2)): (568-583). [PMID:23245208]
74. Mark Turlington,Meredith J Noetzel,Aspen Chun,Ya Zhou,Rocco D Gogliotti,Elizabeth D Nguyen,Karen J Gregory,Paige N Vinson,Jerri M Rook,Kiran K Gogi,Zixiu Xiang,Thomas M Bridges,J Scott Daniels,Carrie Jones,Colleen M Niswender,Jens Meiler,P Jeffrey Conn,Craig W Lindsley,Shaun R Stauffer. (2013-09-21) Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).. Journal of medicinal chemistry, 56 ((20)): (7976-7996). [PMID:24050755]
75. Marieke Voets,Iris Antes,Christiane Scherer,Ursula Müller-Vieira,Klaus Biemel,Catherine Barassin,Sandrine Marchais-Oberwinkler,Rolf W Hartmann. (2005-10-14) Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.. Journal of medicinal chemistry, 48 ((21)): (6632-6642). [PMID:16220979]
76. Thomas Lübbers,Markus Böhringer,Luca Gobbi,Michael Hennig,Daniel Hunziker,Bernd Kuhn,Bernd Löffler,Patrizio Mattei,Robert Narquizian,Jens-Uwe Peters,Yves Ruff,Hans Peter Wessel,Pierre Wyss. (2007-04-10) 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors.. Bioorganic & medicinal chemistry letters, 17 ((11)): (2966-2970). [PMID:17418568]
77. Ralf Heim,Simon Lucas,Cornelia M Grombein,Christina Ries,Katarzyna E Schewe,Matthias Negri,Ursula Müller-Vieira,Barbara Birk,Rolf W Hartmann. (2008-08-05) Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.. Journal of medicinal chemistry, 51 ((16)): (5064-5074). [PMID:18672861]
78. Qingzhong Hu,Matthias Negri,Kerstin Jahn-Hoffmann,Yan Zhuang,Sureyya Olgen,Marc Bartels,Ursula Müller-Vieira,Thomas Lauterbach,Rolf W Hartmann. (2008-08-05) Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.. Bioorganic & medicinal chemistry, 16 ((16)): (7715-7727). [PMID:18674917]
79. Paul A Brough,Xavier Barril,Jenifer Borgognoni,Patrick Chene,Nicholas G M Davies,Ben Davis,Martin J Drysdale,Brian Dymock,Suzanne A Eccles,Carlos Garcia-Echeverria,Christophe Fromont,Angela Hayes,Roderick E Hubbard,Allan M Jordan,Michael Rugaard Jensen,Andrew Massey,Angela Merrett,Antony Padfield,Rachel Parsons,Thomas Radimerski,Florence I Raynaud,Alan Robertson,Stephen D Roughley,Joseph Schoepfer,Heather Simmonite,Swee Y Sharp,Allan Surgenor,Melanie Valenti,Steven Walls,Paul Webb,Mike Wood,Paul Workman,Lisa Wright. (2009-07-21) Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.. Journal of medicinal chemistry, 52 ((15)): (4794-4809). [PMID:19610616]
80. Jutamas Jiaranaikulwanitch,Chantana Boonyarat,Valery V Fokin,Opa Vajragupta. (2010-10-15) Triazolyl tryptoline derivatives as β-secretase inhibitors.. Bioorganic & medicinal chemistry letters, 20 ((22)): (6572-6576). [PMID:20943389]
81. Guangxin Xia,Mengzhu Xue,Lin Liu,Jianxin Yu,Haiyan Liu,Ping Li,Jianfa Wang,Yanlian Li,Bing Xiong,Jingkang Shen. (2011-08-30) Potent and novel 11β-HSD1 inhibitors identified from shape and docking based virtual screening.. Bioorganic & medicinal chemistry letters, 21 ((19)): (5739-5744). [PMID:21873057]
82. Yuusuke Tamura,Kyouhei Hayashi,Naoki Omori,Yuji Nishiura,Kana Watanabe,Nobuyuki Tanaka,Masahiko Fujioka,Naoki Kouyama,Akira Yukimasa,Yukari Tanaka,Takeshi Chiba,Hideki Tanioka,Hirohide Nambu,Hideo Yukioka,Hiroki Sato,Takayuki Okuno. (2012-12-05) Identification of a novel benzimidazole derivative as a highly potent NPY Y5 receptor antagonist with an anti-obesity profile.. Bioorganic & medicinal chemistry letters, 23 ((1)): (90-95). [PMID:23206862]
83. James A D Good,Fang Wang,Oliver Rath,Hung Yi Kristal Kaan,Sandeep K Talapatra,Dawid Podgórski,Simon P MacKay,Frank Kozielski. (2013-02-12) Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models.. Journal of medicinal chemistry, 56 ((5)): (1878-1893). [PMID:23394180]
84. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G.. (2004) Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.. Bioorg Med Chem Lett, 14 (13): (3595-3599). [PMID:15177482] [10.1016/j.bmcl.2004.03.106]
85. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G.. (2004) SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.. Bioorg Med Chem Lett, 14 (13): (3601-3605). [PMID:15177483] [10.1016/j.bmcl.2004.03.111]
86. Voets M, Antes I, Scherer C, Müller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.. (2006) Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.. J Med Chem, 49 (7): (2222-2231). [PMID:16570918] [10.1021/jm060055x]
87. Young WB, Mordenti J, Torkelson S, Shrader WD, Kolesnikov A, Rai R, Liu L, Hu H, Leahy EM, Green MJ, Sprengeler PA, Katz BA, Yu C, Janc JW, Elrod KC, Marzec UM, Hanson SR.. (2006) Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.. Bioorg Med Chem Lett, 16 (7): (2037-2041). [PMID:16412633] [10.1016/j.bmcl.2005.12.059]
88. Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A, Nudelman R, Kauffman M, Noiman S.. (2006) An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.. J Med Chem, 49 (11): (3116-3135). [PMID:16722631] [10.1021/jm0508641]
89. Madar DJ, Kopecka H, Pireh D, Yong H, Pei Z, Li X, Wiedeman PE, Djuric SW, Von Geldern TW, Fickes MG, Bhagavatula L, McDermott T, Wittenberger S, Richards SJ, Longenecker KL, Stewart KD, Lubben TH, Ballaron SJ, Stashko MA, Long MA, Wells H, Zinker BA, Mika AK, Beno DW, Kempf-Grote AJ, Polakowski J, Segreti J, Reinhart GA, Fryer RM, Sham HL, Trevillyan JM.. (2006) Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.. J Med Chem, 49 (21): (6416-6420). [PMID:17034148] [10.1021/jm060777o]
90. Pei Z, Li X, von Geldern TW, Madar DJ, Longenecker K, Yong H, Lubben TH, Stewart KD, Zinker BA, Backes BJ, Judd AS, Mulhern M, Ballaron SJ, Stashko MA, Mika AK, Beno DW, Reinhart GA, Fryer RM, Preusser LC, Kempf-Grote AJ, Sham HL, Trevillyan JM.. (2006) Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.. J Med Chem, 49 (22): (6439-6442). [PMID:17064063] [10.1021/jm060955d]
91. Kaila N, Janz K, DeBernardo S, Bedard PW, Camphausen RT, Tam S, Tsao DH, Keith JC, Nickerson-Nutter C, Shilling A, Young-Sciame R, Wang Q.. (2007) Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.. J Med Chem, 50 (1): (21-39). [PMID:17201408] [10.1021/jm0602256]
92. Liverton NJ, Bednar RA, Bednar B, Butcher JW, Claiborne CF, Claremon DA, Cunningham M, DiLella AG, Gaul SL, Libby BE, Lyle EA, Lynch JJ, McCauley JA, Mosser SD, Nguyen KT, Stump GL, Sun H, Wang H, Yergey J, Koblan KS.. (2007) Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.. J Med Chem, 50 (4): (807-819). [PMID:17249648] [10.1021/jm060983w]
93. Rudolph J, Chen L, Majumdar D, Bullock WH, Burns M, Claus T, Dela Cruz FE, Daly M, Ehrgott FJ, Johnson JS, Livingston JN, Schoenleber RW, Shapiro J, Yang L, Tsutsumi M, Ma X.. (2007) Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.. J Med Chem, 50 (5): (984-1000). [PMID:17274610] [10.1021/jm061299k]
94. Garzya V, Forbes IT, Gribble AD, Hadley MS, Lightfoot AP, Payne AH, Smith AB, Douglas SE, Cooper DG, Stansfield IG, Meeson M, Dodds EE, Jones DN, Wood M, Reavill C, Scorer CA, Worby A, Riley G, Eddershaw P, Ioannou C, Donati D, Hagan JJ, Ratti EA.. (2007) Studies towards the identification of a new generation of atypical antipsychotic agents.. Bioorg Med Chem Lett, 17 (2): (400-405). [PMID:17084080] [10.1016/j.bmcl.2006.10.036]
95. Wilson DP, Wan ZK, Xu WX, Kirincich SJ, Follows BC, Joseph-McCarthy D, Foreman K, Moretto A, Wu J, Zhu M, Binnun E, Zhang YL, Tam M, Erbe DV, Tobin J, Xu X, Leung L, Shilling A, Tam SY, Mansour TS, Lee J.. (2007) Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site.. J Med Chem, 50 (19): (4681-4698). [PMID:17705360] [10.1021/jm0702478]
96. Reck F, Zhou F, Eyermann CJ, Kern G, Carcanague D, Ioannidis G, Illingworth R, Poon G, Gravestock MB.. (2007) Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.. J Med Chem, 50 (20): (4868-4881). [PMID:17722903] [10.1021/jm070428+]
97. Backes BJ, Longenecker K, Hamilton GL, Stewart K, Lai C, Kopecka H, von Geldern TW, Madar DJ, Pei Z, Lubben TH, Zinker BA, Tian Z, Ballaron SJ, Stashko MA, Mika AK, Beno DW, Kempf-Grote AJ, Black-Schaefer C, Sham HL, Trevillyan JM.. (2007) Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.. Bioorg Med Chem Lett, 17 (7): (2005-2012). [PMID:17276063] [10.1016/j.bmcl.2007.01.026]
98. Thurmond J, Butchbach ME, Palomo M, Pease B, Rao M, Bedell L, Keyvan M, Pai G, Mishra R, Haraldsson M, Andresson T, Bragason G, Thosteinsdottir M, Bjornsson JM, Coovert DD, Burghes AH, Gurney ME, Singh J.. (2008) Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.. J Med Chem, 51 (3): (449-469). [PMID:18205293] [10.1021/jm061475p]
99. Watson RJ, Allen DR, Birch HL, Chapman GA, Galvin FC, Jopling LA, Knight RL, Meier D, Oliver K, Meissner JW, Owen DA, Thomas EJ, Tremayne N, Williams SC.. (2008) Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives.. Bioorg Med Chem Lett, 18 (1): (147-151). [PMID:18032038] [10.1016/j.bmcl.2007.10.109]
100. Zhang X, Rueter JK, Chen Y, Moorjani M, Lanier MC, Lin E, Gross RS, Tellew JE, Williams JP, Lechner SM, Markison S, Joswig T, Malany S, Santos M, Castro-Palomino JC, Crespo MI, Prat M, Gual S, Díaz JL, Saunders J, Slee DH.. (2008) Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.. Bioorg Med Chem Lett, 18 (6): (1778-1783). [PMID:18329269] [10.1016/j.bmcl.2008.02.032]
101. Knight RL, Allen DR, Birch HL, Chapman GA, Galvin FC, Jopling LA, Lock CJ, Meissner JW, Owen DA, Raphy G, Watson RJ, Williams SC.. (2008) Development of CXCR3 antagonists. Part 4: discovery of 2-amino-(4-tropinyl)quinolines.. Bioorg Med Chem Lett, 18 (2): (629-633). [PMID:18068363] [10.1016/j.bmcl.2007.11.075]
102. Santella JB, Gardner DS, Yao W, Shi C, Reddy P, Tebben AJ, DeLucca GV, Wacker DA, Watson PS, Welch PK, Wadman EA, Davies P, Solomon KA, Graden DM, Yeleswaram S, Mandlekar S, Kariv I, Decicco CP, Ko SS, Carter PH, Duncia JV.. (2008) From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis.. Bioorg Med Chem Lett, 18 (2): (576-585). [PMID:18096386] [10.1016/j.bmcl.2007.11.067]
103. Frotscher M, Ziegler E, Marchais-Oberwinkler S, Kruchten P, Neugebauer A, Fetzer L, Scherer C, Müller-Vieira U, Messinger J, Thole H, Hartmann RW.. (2008) Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.. J Med Chem, 51 (7): (2158-2169). [PMID:18324762] [10.1021/jm701447v]
104. Cai ZW, Wei D, Borzilleri RM, Qian L, Kamath A, Mortillo S, Wautlet B, Henley BJ, Jeyaseelan R, Tokarski J, Hunt JT, Bhide RS, Fargnoli J, Lombardo LJ.. (2008) Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.. Bioorg Med Chem Lett, 18 (4): (1354-1358). [PMID:18221875] [10.1016/j.bmcl.2008.01.012]
105. Crosignani S, Page P, Missotten M, Colovray V, Cleva C, Arrighi JF, Atherall J, Macritchie J, Martin T, Humbert Y, Gaudet M, Pupowicz D, Maio M, Pittet PA, Golzio L, Giachetti C, Rocha C, Bernardinelli G, Filinchuk Y, Scheer A, Schwarz MK, Chollet A.. (2008) Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.. J Med Chem, 51 (7): (2227-2243). [PMID:18318469] [10.1021/jm701383e]
106. Wijtmans M, Celanire S, Snip E, Gillard MR, Gelens E, Collart PP, Venhuis BJ, Christophe B, Hulscher S, van der Goot H, Lebon F, Timmerman H, Bakker RA, Lallemand BI, Leurs R, Talaga PE, de Esch IJ.. (2008) 4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists.. J Med Chem, 51 (10): (2944-2953). [PMID:18433114] [10.1021/jm7014149]
107. Angell R, Aston NM, Bamborough P, Buckton JB, Cockerill S, deBoeck SJ, Edwards CD, Holmes DS, Jones KL, Laine DI, Patel S, Smee PA, Smith KJ, Somers DO, Walker AL.. (2008) Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.. Bioorg Med Chem Lett, 18 (15): (4428-4432). [PMID:18614366] [10.1016/j.bmcl.2008.06.048]
108. Degnan AP, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Denton R, Han X, Macci R, Mathias NR, Moench P, Pin SS, Ren SX, Schartman R, Signor LJ, Thalody G, Widmann KA, Xu C, Macor JE, Dubowchik GM.. (2008) Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure.. J Med Chem, 51 (16): (4858-4861). [PMID:18665579] [10.1021/jm800546t]
109. Kim RM, Chang J, Lins AR, Brady E, Candelore MR, Dallas-Yang Q, Ding V, Dragovic J, Iliff S, Jiang G, Mock S, Qureshi S, Saperstein R, Szalkowski D, Tamvakopoulos C, Tota L, Wright M, Yang X, Tata JR, Chapman K, Zhang BB, Parmee ER.. (2008) Discovery of potent, orally active benzimidazole glucagon receptor antagonists.. Bioorg Med Chem Lett, 18 (13): (3701-3705). [PMID:18539028] [10.1016/j.bmcl.2008.05.072]
110. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P.. (2008) Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.. J Med Chem, 51 (21): (6642-6645). [PMID:18834107] [10.1021/jm800986w]
111. Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, Kruchten P, Oster A, Frotscher M, Birk B, Hartmann RW.. (2008) Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).. J Med Chem, 51 (21): (6725-6739). [PMID:18855374] [10.1021/jm8006917]
112. Gopalsamy A, Shi M, Stauffer B, Bahat R, Billiard J, Ponce-de-Leon H, Seestaller-Wehr L, Fukayama S, Mangine A, Moran R, Krishnamurthy G, Bodine P.. (2008) Identification of diarylsulfone sulfonamides as secreted frizzled related protein-1 (sFRP-1) inhibitors.. J Med Chem, 51 (24): (7670-7672). [PMID:19053830] [10.1021/jm801069w]
113. Jones CD, Andrews DM, Barker AJ, Blades K, Daunt P, East S, Geh C, Graham MA, Johnson KM, Loddick SA, McFarland HM, McGregor A, Moss L, Rudge DA, Simpson PB, Swain ML, Tam KY, Tucker JA, Walker M.. (2008) The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.. Bioorg Med Chem Lett, 18 (24): (6369-6373). [PMID:18996007] [10.1016/j.bmcl.2008.10.102]
114. Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, Klinghofer V, Johnson EF, Donawho CK, Frost DJ, Bontcheva-Diaz V, Bouska JJ, Osterling DJ, Olson AM, Marsh KC, Luo Y, Giranda VL.. (2009) Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.. J Med Chem, 52 (2): (514-523). [PMID:19143569] [10.1021/jm801171j]
115. Pettus LH, Xu S, Cao GQ, Chakrabarti PP, Rzasa RM, Sham K, Wurz RP, Zhang D, Middleton S, Henkle B, Plant MH, Saris CJ, Sherman L, Wong LM, Powers DA, Tudor Y, Yu V, Lee MR, Syed R, Hsieh F, Tasker AS.. (2008) 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.. J Med Chem, 51 (20): (6280-6292). [PMID:18817364] [10.1021/jm8005405]
116. Vu CB, Bemis JE, Disch JS, Ng PY, Nunes JJ, Milne JC, Carney DP, Lynch AV, Smith JJ, Lavu S, Lambert PD, Gagne DJ, Jirousek MR, Schenk S, Olefsky JM, Perni RB.. (2009) Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.. J Med Chem, 52 (5): (1275-1283). [PMID:19199480] [10.1021/jm8012954]
117. Hubbard RD, Bamaung NY, Fidanze SD, Erickson SA, Palazzo F, Wilsbacher JL, Zhang Q, Tucker LA, Hu X, Kovar P, Osterling DJ, Johnson EF, Bouska J, Wang J, Davidsen SK, Bell RL, Sheppard GS.. (2009) Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.. Bioorg Med Chem Lett, 19 (6): (1718-1721). [PMID:19217287] [10.1016/j.bmcl.2009.01.086]
118. Vachal P, Fletcher JM, Fong TM, Huang CC, Lao J, Xiao JC, Shen CP, Strack AM, Shearman L, Stribling S, Chen RZ, Frassetto A, Tong X, Wang J, Ball RG, Tsou NN, Hickey GJ, Thompson DF, Faidley TD, Nicolich S, Achanfuo-Yeboah J, Hora DF, Hale JJ, Hagmann WK.. (2009) 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.. J Med Chem, 52 (8): (2550-2558). [PMID:19320488] [10.1021/jm900063x]
119. Marquis RW, Lago AM, Callahan JF, Trout RE, Gowen M, DelMar EG, Van Wagenen BC, Logan S, Shimizu S, Fox J, Nemeth EF, Yang Z, Roethke T, Smith BR, Ward KW, Lee J, Keenan RM, Bhatnagar P.. (2009) Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.. J Med Chem, 52 (13): (3982-3993). [PMID:19492813] [10.1021/jm900364m]
120. Charrier N, Clarke B, Cutler L, Demont E, Dingwall C, Dunsdon R, Hawkins J, Howes C, Hubbard J, Hussain I, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D, Walter DS, Wayne G.. (2009) Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.. Bioorg Med Chem Lett, 19 (13): (3664-3668). [PMID:19428244] [10.1016/j.bmcl.2009.03.165]
121. Rano TA, Sieber-McMaster E, Pelton PD, Yang M, Demarest KT, Kuo GH.. (2009) Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform.. Bioorg Med Chem Lett, 19 (9): (2456-2460). [PMID:19339179] [10.1016/j.bmcl.2009.03.051]
122. Ammirati MJ, Andrews KM, Boyer DD, Brodeur AM, Danley DE, Doran SD, Hulin B, Liu S, McPherson RK, Orena SJ, Parker JC, Polivkova J, Qiu X, Soglia CB, Treadway JL, VanVolkenburg MA, Wilder DC, Piotrowski DW.. (2009) (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.. Bioorg Med Chem Lett, 19 (7): (1991-1995). [PMID:19275964] [10.1016/j.bmcl.2009.02.041]
123. Liu W, Liu K, Wood HB, McCann ME, Doebber TW, Chang CH, Akiyama TE, Einstein M, Berger JP, Meinke PT.. (2009) Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.. J Med Chem, 52 (14): (4443-4453). [PMID:19530681] [10.1021/jm900367w]
124. Lumeras W, Caturla F, Vidal L, Esteve C, Balagué C, Orellana A, Domínguez M, Roca R, Huerta JM, Godessart N, Vidal B.. (2009) Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.. J Med Chem, 52 (17): (5531-5545). [PMID:19678708] [10.1021/jm9008604]
125. Li W, Li J, Wu Y, Rancati F, Vallese S, Raveglia L, Wu J, Hotchandani R, Fuller N, Cunningham K, Morgan P, Fish S, Krykbaev R, Xu X, Tam S, Goldman SJ, Abraham W, Williams C, Sypek J, Mansour TS.. (2009) Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.. J Med Chem, 52 (17): (5408-5419). [PMID:19725580] [10.1021/jm900809r]
126. Stearns BA, Baccei C, Bain G, Broadhead A, Clark RC, Coate H, Evans JF, Fagan P, Hutchinson JH, King C, Lee C, Lorrain DS, Prasit P, Prodanovich P, Santini A, Scott JM, Stock NS, Truong YP.. (2009) Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.. Bioorg Med Chem Lett, 19 (16): (4647-4651). [PMID:19608418] [10.1016/j.bmcl.2009.06.085]
127. Pisani L, Muncipinto G, Miscioscia TF, Nicolotti O, Leonetti F, Catto M, Caccia C, Salvati P, Soto-Otero R, Mendez-Alvarez E, Passeleu C, Carotti A.. (2009) Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor.. J Med Chem, 52 (21): (6685-6706). [PMID:19810674] [10.1021/jm9010127]
128. Marquis RW, Lago AM, Callahan JF, Rahman A, Dong X, Stroup GB, Hoffman S, Gowen M, DelMar EG, Van Wagenen BC, Logan S, Shimizu S, Fox J, Nemeth EF, Roethke T, Smith BR, Ward KW, Bhatnagar P.. (2009) Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.. J Med Chem, 52 (21): (6599-6605). [PMID:19821575] [10.1021/jm900563e]
129. Bey E, Marchais-Oberwinkler S, Negri M, Kruchten P, Oster A, Klein T, Spadaro A, Werth R, Frotscher M, Birk B, Hartmann RW.. (2009) New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.. J Med Chem, 52 (21): (6724-6743). [PMID:19831396] [10.1021/jm901195w]
130. Blass BE, Fensome A, Trybulski E, Magolda R, Gardell SJ, Liu K, Samuel M, Feingold I, Huselton C, Jackson CM, Djandjighian L, Ho D, Hennan J, Janusz JM.. (2009) Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.. J Med Chem, 52 (21): (6531-6534). [PMID:19888755] [10.1021/jm901042m]
131. Li J, Kaoud TS, Laroche C, Dalby KN, Kerwin SM.. (2009) Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles.. Bioorg Med Chem Lett, 19 (22): (6293-6297). [PMID:19822424] [10.1016/j.bmcl.2009.09.094]
132. Ghirmai S, Azar MR, Cashman JR.. (2009) Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.. Bioorg Med Chem, 17 (18): (6671-6681). [PMID:19683449] [10.1016/j.bmc.2009.07.069]
133. Kallander LS, Washburn DG, Hoang TH, Frazee JS, Stoy P, Johnson L, Lu Q, Hammond M, Barton LS, Patterson JR, Azzarano LM, Nagilla R, Madauss KP, Williams SP, Stewart EL, Duraiswami C, Grygielko ET, Xu X, Laping NJ, Bray JD, Thompson SK.. (2010) Improving the developability profile of pyrrolidine progesterone receptor partial agonists.. Bioorg Med Chem Lett, 20 (1): (371-374). [PMID:19926282] [10.1016/j.bmcl.2009.10.092]
134. Haydar SN, Yun H, Andrae PM, Mattes J, Zhang J, Kramer A, Smith DL, Huselton C, Graf R, Aschmies S, Schechter LE, Comery TA, Robichaud AJ.. (2010) 5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.. J Med Chem, 53 (6): (2521-2527). [PMID:20170099] [10.1021/jm901674f]
135. Ahmad S, Ngu K, Miller KJ, Wu G, Hung CP, Malmstrom S, Zhang G, O'Tanyi E, Keim WJ, Cullen MJ, Rohrbach KW, Thomas M, Ung T, Qu Q, Gan J, Narayanan R, Pelleymounter MA, Robl JA.. (2010) Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.. Bioorg Med Chem Lett, 20 (3): (1128-1133). [PMID:20022752] [10.1016/j.bmcl.2009.12.014]
136. Pettus LH, Wurz RP, Xu S, Herberich B, Henkle B, Liu Q, McBride HJ, Mu S, Plant MH, Saris CJ, Sherman L, Wong LM, Chmait S, Lee MR, Mohr C, Hsieh F, Tasker AS.. (2010) Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.. J Med Chem, 53 (7): (2973-2985). [PMID:20218619] [10.1021/jm100095x]
137. Li J, Kennedy LJ, Shi Y, Tao S, Ye XY, Chen SY, Wang Y, Hernández AS, Wang W, Devasthale PV, Chen S, Lai Z, Zhang H, Wu S, Smirk RA, Bolton SA, Ryono DE, Zhang H, Lim NK, Chen BC, Locke KT, O'Malley KM, Zhang L, Srivastava RA, Miao B, Meyers DS, Monshizadegan H, Search D, Grimm D, Zhang R, Harrity T, Kunselman LK, Cap M, Kadiyala P, Hosagrahara V, Zhang L, Xu C, Li YX, Muckelbauer JK, Chang C, An Y, Krystek SR, Blanar MA, Zahler R, Mukherjee R, Cheng PT, Tino JA.. (2010) Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).. J Med Chem, 53 (7): (2854-2864). [PMID:20218621] [10.1021/jm9016812]
138. Yan L, Huo P, Debenham JS, Madsen-Duggan CB, Lao J, Chen RZ, Xiao JC, Shen CP, Stribling DS, Shearman LP, Strack AM, Tsou N, Ball RG, Wang J, Tong X, Bateman TJ, Reddy VB, Fong TM, Hale JJ.. (2010) Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.. J Med Chem, 53 (10): (4028-4037). [PMID:20423086] [10.1021/jm100023j]
139. Ray S, Madrid PB, Catz P, LeValley SE, Furniss MJ, Rausch LL, Guy RK, DeRisi JL, Iyer LV, Green CE, Mirsalis JC.. (2010) Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.. J Med Chem, 53 (9): (3685-3695). [PMID:20361799] [10.1021/jm100057h]
140. Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, Wilsher NE, Martins V, Reynisson J, Atrash B, Faisal A, Urban F, Valenti M, de Haven Brandon A, Box G, Raynaud FI, Workman P, Eccles SA, Bayliss R, Blagg J, Linardopoulos S, McDonald E.. (2010) Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.. J Med Chem, 53 (14): (5213-5228). [PMID:20565112] [10.1021/jm100262j]
141. Véniant MM, Hale C, Hungate RW, Gahm K, Emery MG, Jona J, Joseph S, Adams J, Hague A, Moniz G, Zhang J, Bartberger MD, Li V, Syed R, Jordan S, Komorowski R, Chen MM, Cupples R, Kim KW, St Jean DJ, Johansson L, Henriksson MA, Williams M, Vallgårda J, Fotsch C, Wang M.. (2010) Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).. J Med Chem, 53 (11): (4481-4487). [PMID:20465278] [10.1021/jm100242d]
142. Ladduwahetty T, Gilligan M, Humphries A, Merchant KJ, Fish R, McAlister G, Ivarsson M, Dominguez M, O'Connor D, MacLeod AM.. (2010) Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists for the treatment of sleep disorders.. Bioorg Med Chem Lett, 20 (12): (3708-3712). [PMID:20493697] [10.1016/j.bmcl.2010.04.090]
143. Clarke B, Cutler L, Demont E, Dingwall C, Dunsdon R, Hawkins J, Howes C, Hussain I, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D, Walter DS, Wayne G.. (2010) BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.. Bioorg Med Chem Lett, 20 (15): (4639-4644). [PMID:20579874] [10.1016/j.bmcl.2010.05.111]
144. Ward SE, Harries M, Aldegheri L, Andreotti D, Ballantine S, Bax BD, Harris AJ, Harker AJ, Lund J, Melarange R, Mingardi A, Mookherjee C, Mosley J, Neve M, Oliosi B, Profeta R, Smith KJ, Smith PW, Spada S, Thewlis KM, Yusaf SP.. (2010) Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator.. J Med Chem, 53 (15): (5801-5812). [PMID:20614889] [10.1021/jm1005429]
145. Arhancet GB, Woodard SS, Iyanar K, Case BL, Woerndle R, Dietz JD, Garland DJ, Collins JT, Payne MA, Blinn JR, Pomposiello SI, Hu X, Heron MI, Huang HC, Lee LF.. (2010) Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.. J Med Chem, 53 (16): (5970-5978). [PMID:20672820] [10.1021/jm100506y]
146. Tipparaju SK, Muench SP, Mui EJ, Ruzheinikov SN, Lu JZ, Hutson SL, Kirisits MJ, Prigge ST, Roberts CW, Henriquez FL, Kozikowski AP, Rice DW, McLeod RL.. (2010) Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase.. J Med Chem, 53 (17): (6287-6300). [PMID:20698542] [10.1021/jm9017724]
147. Gianotti M, Botta M, Brough S, Carletti R, Castiglioni E, Corti C, Dal-Cin M, Delle Fratte S, Korajac D, Lovric M, Merlo G, Mesic M, Pavone F, Piccoli L, Rast S, Roscic M, Sava A, Smehil M, Stasi L, Togninelli A, Wigglesworth MJ.. (2010) Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.. J Med Chem, 53 (21): (7778-7795). [PMID:20942472] [10.1021/jm100856p]
148. Jeong S, Nguyen PD, Desta Z.. (2009) Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A.. Antimicrob Agents Chemother, 53 (2): (541-551). [PMID:19029318] [10.1128/aac.01123-08]
149. Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.. (2011) Potent and selective thiophene urea-templated inhibitors of S6K.. Bioorg Med Chem Lett, 21 (2): (849-852). [PMID:21185721] [10.1016/j.bmcl.2010.11.069]
150. Gilbert AM, Bursavich MG, Lombardi S, Adedoyin A, Dwyer JM, Hughes Z, Kern JC, Khawaja X, Rosenzweig-Lipson S, Moore WJ, Neal SJ, Olsen M, Rizzo SJ, Springer D.. (2011) 3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.. Bioorg Med Chem Lett, 21 (1): (195-199). [PMID:21126874] [10.1016/j.bmcl.2010.11.038]
151. Richter HG, Benson GM, Blum D, Chaput E, Feng S, Gardes C, Grether U, Hartman P, Kuhn B, Martin RE, Plancher JM, Rudolph MG, Schuler F, Taylor S, Bleicher KH.. (2011) Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes.. Bioorg Med Chem Lett, 21 (1): (191-194). [PMID:21134747] [10.1016/j.bmcl.2010.11.039]
152. Manning DD, Cioffi CL, Usyatinsky A, Fitzpatrick K, Masih L, Guo C, Zhang Z, Choo SH, Sikkander MI, Ryan KN, Naginskaya J, Hassler C, Dobritsa S, Wierschke JD, Earley WG, Butler AS, Brady CA, Barnes NM, Cohen ML, Guzzo PR.. (2011) Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.. Bioorg Med Chem Lett, 21 (1): (58-61). [PMID:21146988] [10.1016/j.bmcl.2010.11.080]
153. Barker RH, Liu H, Hirth B, Celatka CA, Fitzpatrick R, Xiang Y, Willert EK, Phillips MA, Kaiser M, Bacchi CJ, Rodriguez A, Yarlett N, Klinger JD, Sybertz E.. (2009) Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis.. Antimicrob Agents Chemother, 53 (5): (2052-2058). [PMID:19289530] [10.1128/aac.01674-08]
154. Zhang Z, Wallace MB, Feng J, Stafford JA, Skene RJ, Shi L, Lee B, Aertgeerts K, Jennings A, Xu R, Kassel DB, Kaldor SW, Navre M, Webb DR, Gwaltney SL.. (2011) Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.. J Med Chem, 54 (2): (510-524). [PMID:21186796] [10.1021/jm101016w]
155. Marchais-Oberwinkler S, Wetzel M, Ziegler E, Kruchten P, Werth R, Henn C, Hartmann RW, Frotscher M.. (2011) New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.. J Med Chem, 54 (2): (534-547). [PMID:21189020] [10.1021/jm1009082]
156. Stock N, Volkots D, Stebbins K, Broadhead A, Stearns B, Roppe J, Parr T, Baccei C, Bain G, Chapman C, Correa L, Darlington J, King C, Lee C, Lorrain DS, Prodanovich P, Santini A, Evans JF, Hutchinson JH, Prasit P.. (2011) Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.. Bioorg Med Chem Lett, 21 (3): (1036-1040). [PMID:21211969] [10.1016/j.bmcl.2010.12.016]
157. Engers DW, Field JR, Le U, Zhou Y, Bolinger JD, Zamorano R, Blobaum AL, Jones CK, Jadhav S, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR.. (2011) Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats.. J Med Chem, 54 (4): (1106-1110). [PMID:21247167] [10.1021/jm101271s]
158. Bass JY, Caravella JA, Chen L, Creech KL, Deaton DN, Madauss KP, Marr HB, McFadyen RB, Miller AB, Mills WY, Navas F, Parks DJ, Smalley TL, Spearing PK, Todd D, Williams SP, Wisely GB.. (2011) Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.. Bioorg Med Chem Lett, 21 (4): (1206-1213). [PMID:21256005] [10.1016/j.bmcl.2010.12.089]
159. Patch RJ, Searle LL, Kim AJ, De D, Zhu X, Askari HB, O'Neill JC, Abad MC, Rentzeperis D, Liu J, Kemmerer M, Lin L, Kasturi J, Geisler JG, Lenhard JM, Player MR, Gaul MD.. (2011) Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents.. J Med Chem, 54 (3): (788-808). [PMID:21218783] [10.1021/jm101063h]
160. Shao L, Hewitt MC, Wang F, Malcolm SC, Ma J, Campbell JE, Campbell UC, Engel SR, Spicer NA, Hardy LW, Schreiber R, Spear KL, Varney MA.. (2011) Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.. Bioorg Med Chem Lett, 21 (5): (1438-1441). [PMID:21310609] [10.1016/j.bmcl.2011.01.016]
161. Shao L, Hewitt MC, Wang F, Malcolm SC, Ma J, Campbell JE, Campbell UC, Engel SR, Spicer NA, Hardy LW, Schreiber R, Spear KL, Varney MA.. (2011) Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.. Bioorg Med Chem Lett, 21 (5): (1434-1437). [PMID:21310612] [10.1016/j.bmcl.2011.01.019]
162. Andrews KM, Beebe DA, Benbow JW, Boyer DA, Doran SD, Hui Y, Liu S, McPherson RK, Neagu C, Parker JC, Piotrowski DW, Schneider SR, Treadway JL, VanVolkenberg MA, Zembrowski WJ.. (2011) 1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.. Bioorg Med Chem Lett, 21 (6): (1810-1814). [PMID:21324688] [10.1016/j.bmcl.2011.01.055]
163. Laborde E, Macsata RW, Meng F, Peterson BT, Robinson L, Schow SR, Simon RJ, Xu H, Baba K, Inagaki H, Ishiwata Y, Jomori T, Matsumoto Y, Miyachi A, Nakamura T, Okamoto M, Handel TM, Bernard CC.. (2011) Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.. J Med Chem, 54 (6): (1667-1681). [PMID:21341682] [10.1021/jm1012903]
164. Lesuisse D, Mauger J, Nemecek C, Maignan S, Boiziau J, Harlow G, Hittinger A, Ruf S, Strobel H, Nair A, Ritter K, Malleron JL, Dagallier A, El-Ahmad Y, Guilloteau JP, Guizani H, Bouchard H, Venot C.. (2011) Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.. Bioorg Med Chem Lett, 21 (8): (2224-2228). [PMID:21441024] [10.1016/j.bmcl.2011.03.003]
165. Xia G, Benmohamed R, Kim J, Arvanites AC, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB.. (2011) Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis.. J Med Chem, 54 (7): (2409-2421). [PMID:21375347] [10.1021/jm101549k]
166. Lucas S, Negri M, Heim R, Zimmer C, Hartmann RW.. (2011) Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.. J Med Chem, 54 (7): (2307-2319). [PMID:21384875] [10.1021/jm101470k]
167. Qian Y, Wertheimer SJ, Ahmad M, Cheung AW, Firooznia F, Hamilton MM, Hayden S, Li S, Marcopulos N, McDermott L, Tan J, Yun W, Guo L, Pamidimukkala A, Chen Y, Huang KS, Ramsey GB, Whittard T, Conde-Knape K, Taub R, Rondinone CM, Tilley J, Bolin D.. (2011) Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes.. J Med Chem, 54 (7): (2433-2446). [PMID:21413799] [10.1021/jm101580m]
168. Shiozaki M, Maeda K, Miura T, Kotoku M, Yamasaki T, Matsuda I, Aoki K, Yasue K, Imai H, Ubukata M, Suma A, Yokota M, Hotta T, Tanaka M, Hase Y, Haas J, Fryer AM, Laird ER, Littmann NM, Andrews SW, Josey JA, Mimura T, Shinozaki Y, Yoshiuchi H, Inaba T.. (2011) Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.. J Med Chem, 54 (8): (2839-2863). [PMID:21417219] [10.1021/jm101609j]
169. Zehnder L, Bennett M, Meng J, Huang B, Ninkovic S, Wang F, Braganza J, Tatlock J, Jewell T, Zhou JZ, Burke B, Wang J, Maegley K, Mehta PP, Yin MJ, Gajiwala KS, Hickey MJ, Yamazaki S, Smith E, Kang P, Sistla A, Dovalsantos E, Gehring MR, Kania R, Wythes M, Kung PP.. (2011) Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.. J Med Chem, 54 (9): (3368-3385). [PMID:21438541] [10.1021/jm200128m]
170. Kim HJ, Kwak WY, Min JP, Lee JY, Yoon TH, Kim HD, Shin CY, Kim MK, Choi SH, Kim HS, Yang EK, Cheong YH, Chae YN, Park KJ, Jang JM, Choi SJ, Son MH, Kim SH, Yoo M, Lee BJ.. (2011) Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.. Bioorg Med Chem Lett, 21 (12): (3809-3812). [PMID:21570283] [10.1016/j.bmcl.2011.04.029]
171. Nirogi RV, Kothmirkar P, Kambhampati R, Konda JB, Arepalli S, Pamuleti NG, Deshpande AD, Bandyala T, Shinde AK, Dubey PK.. (2010) Novel and Potent 5-Piperazinyl Methyl-N 1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands.. ACS Med Chem Lett, 1 (7): (340-344). [PMID:24900216] [10.1021/ml100101u]
172. Zapf CW, Bloom JD, Li Z, Dushin RG, Nittoli T, Otteng M, Nikitenko A, Golas JM, Liu H, Lucas J, Boschelli F, Vogan E, Olland A, Johnson M, Levin JI.. (2011) Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.. Bioorg Med Chem Lett, 21 (15): (4602-4607). [PMID:21715165] [10.1016/j.bmcl.2011.05.102]
173. Hudkins RL, Raddatz R, Tao M, Mathiasen JR, Aimone LD, Becknell NC, Prouty CP, Knutsen LJ, Yazdanian M, Moachon G, Ator MA, Mallamo JP, Marino MJ, Bacon ER, Williams M.. (2011) Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.. J Med Chem, 54 (13): (4781-4792). [PMID:21634396] [10.1021/jm200401v]
174. Chavez SA, Martinko AJ, Lau C, Pham MN, Cheng K, Bevan DE, Mollnes TE, Yin H.. (2011) Development of β-amino alcohol derivatives that inhibit Toll-like receptor 4 mediated inflammatory response as potential antiseptics.. J Med Chem, 54 (13): (4659-4669). [PMID:21591694] [10.1021/jm2003365]
175. Zhang L, Fan J, Chong JH, Cesena A, Tam BY, Gilson C, Boykin C, Wang D, Aivazian D, Marcotte D, Xiao G, Le Brazidec JY, Piao J, Lundgren K, Hong K, Vu K, Nguyen K, Gan LS, Silvian L, Ling L, Teng M, Reff M, Takeda N, Timple N, Wang Q, Morena R, Khan S, Zhao S, Li T, Lee WC, Taveras AG, Chao J.. (2011) Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).. Bioorg Med Chem Lett, 21 (18): (5633-5637). [PMID:21798738] [10.1016/j.bmcl.2011.06.129]
176. Christiansen E, Urban C, Grundmann M, Due-Hansen ME, Hagesaether E, Schmidt J, Pardo L, Ullrich S, Kostenis E, Kassack M, Ulven T.. (2011) Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.. J Med Chem, 54 (19): (6691-6703). [PMID:21854074] [10.1021/jm2005699]
177. Packiarajan M, Marzabadi MR, Desai M, Lu Y, Noble SA, Wong WC, Jubian V, Chandrasena G, Wolinsky TD, Zhong H, Walker MW, Wiborg O, Andersen K.. (2011) Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.. Bioorg Med Chem Lett, 21 (18): (5436-5441). [PMID:21782428] [10.1016/j.bmcl.2011.06.124]
178. Demont EH, Arpino S, Bit RA, Campbell CA, Deeks N, Desai S, Dowell SJ, Gaskin P, Gray JR, Harrison LA, Haynes A, Heightman TD, Holmes DS, Humphreys PG, Kumar U, Morse MA, Osborne GJ, Panchal T, Philpott KL, Taylor S, Watson R, Willis R, Witherington J.. (2011) Discovery of a brain-penetrant S1P₃-sparing direct agonist of the S1P₁ and S1P₅ receptors efficacious at low oral dose.. J Med Chem, 54 (19): (6724-6733). [PMID:21838322] [10.1021/jm200609t]
179. Sun X, Qiu J, Strong SA, Green LS, Wasley JW, Blonder JP, Colagiovanni DB, Mutka SC, Stout AM, Richards JP, Rosenthal GJ.. (2011) Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.. Bioorg Med Chem Lett, 21 (19): (5849-5853). [PMID:21855338] [10.1016/j.bmcl.2011.07.103]
180. Annedi SC, Maddaford SP, Mladenova G, Ramnauth J, Rakhit S, Andrews JS, Lee DK, Zhang D, Porreca F, Bunton D, Christie L.. (2011) Discovery of N-(3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a selective inhibitor of human neuronal nitric oxide synthase (nNOS) for the treatment of pain.. J Med Chem, 54 (20): (7408-7416). [PMID:21923116] [10.1021/jm201063u]
181. Onda K, Narazaki F, Ishibashi N, Nakanishi K, Sawada Y, Imamura K, Momose K, Furukawa S, Shimada Y, Moriguchi H, Yuda M, Kayakiri H, Ohta M.. (2011) Identification of 4-quinolone derivatives as inhibitors of reactive oxygen species production from human umbilical vein endothelial cells.. Bioorg Med Chem Lett, 21 (22): (6861-6866). [PMID:21963985] [10.1016/j.bmcl.2011.09.015]
182. Lebois EP, Digby GJ, Sheffler DJ, Melancon BJ, Tarr JC, Cho HP, Miller NR, Morrison R, Bridges TM, Xiang Z, Daniels JS, Wood MR, Conn PJ, Lindsley CW.. (2011) Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.. Bioorg Med Chem Lett, 21 (21): (6451-6455). [PMID:21930376] [10.1016/j.bmcl.2011.08.084]
183. Ramnauth J, Speed J, Maddaford SP, Dove P, Annedi SC, Renton P, Rakhit S, Andrews J, Silverman S, Mladenova G, Zinghini S, Nair S, Catalano C, Lee DK, De Felice M, Porreca F.. (2011) Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.. J Med Chem, 54 (15): (5562-5575). [PMID:21699209] [10.1021/jm200648s]
184. Buzard D, Han S, Thoresen L, Moody J, Lopez L, Kawasaki A, Schrader T, Sage C, Gao Y, Edwards J, Barden J, Thatte J, Fu L, Solomon M, Liu L, Al-Shamma H, Gatlin J, Le M, Xing C, Espinola S, Jones RM.. (2011) Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists.. Bioorg Med Chem Lett, 21 (19): (6013-6018). [PMID:21852130] [10.1016/j.bmcl.2011.05.110]
185. Lumeras W, Vidal L, Vidal B, Balagué C, Orellana A, Maldonado M, Domínguez M, Segarra V, Caturla F.. (2011) 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.. J Med Chem, 54 (22): (7899-7910). [PMID:21999461] [10.1021/jm200975u]
186. Chowdhury S, Sessions EH, Pocas JR, Grant W, Schröter T, Lin L, Ruiz C, Cameron MD, Schürer S, LoGrasso P, Bannister TD, Feng Y.. (2011) Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).. Bioorg Med Chem Lett, 21 (23): (7107-7112). [PMID:22004718] [10.1016/j.bmcl.2011.09.083]
187. McNulty J, Nair JJ, Vurgun N, Difrancesco BR, Brown CE, Tsoi B, Crankshaw DJ, Holloway AC.. (2012) Discovery of a novel class of aldol-derived 1,2,3-triazoles: potent and selective inhibitors of human cytochrome P450 19A1 (aromatase).. Bioorg Med Chem Lett, 22 (1): (718-722). [PMID:22079757] [10.1016/j.bmcl.2011.10.039]
188. Powell NA, Kohrt JT, Filipski KJ, Kaufman M, Sheehan D, Edmunds JE, Delaney A, Wang Y, Bourbonais F, Lee DY, Schwende F, Sun F, McConnell P, Catana C, Chen H, Ohren J, Perrin LA.. (2012) Novel and selective spiroindoline-based inhibitors of Sky kinase.. Bioorg Med Chem Lett, 22 (1): (190-193). [PMID:22119469] [10.1016/j.bmcl.2011.11.036]
189. De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S.. (2012) Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.. Bioorg Med Chem Lett, 22 (1): (271-277). [PMID:22153941] [10.1016/j.bmcl.2011.11.034]
190. Brand S, Cleghorn LA, McElroy SP, Robinson DA, Smith VC, Hallyburton I, Harrison JR, Norcross NR, Spinks D, Bayliss T, Norval S, Stojanovski L, Torrie LS, Frearson JA, Brenk R, Fairlamb AH, Ferguson MA, Read KD, Wyatt PG, Gilbert IH.. (2012) Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors.. J Med Chem, 55 (1): (140-152). [PMID:22148754] [10.1021/jm201091t]
191. Brocklehurst KJ, Broo A, Butlin RJ, Brown HS, Clarke DS, Davidsson Ö, Goldberg K, Groombridge SD, Kelly EE, Leach A, McKerrecher D, O'Donnell C, Poucher S, Schofield P, Scott JS, Teague J, Westgate L, Wood MJ.. (2011) Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.. Bioorg Med Chem Lett, 21 (24): (7310-7316). [PMID:22061639] [10.1016/j.bmcl.2011.10.033]
192. Davies DJ, Crowe M, Lucas N, Quinn J, Miller DD, Pritchard S, Grose D, Bettini E, Calcinaghi N, Virginio C, Abberley L, Goldsmith P, Michel AD, Chessell IP, Kew JN, Miller ND, Gunthorpe MJ.. (2012) A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.. Bioorg Med Chem Lett, 22 (7): (2620-2623). [PMID:22366657] [10.1016/j.bmcl.2012.01.108]
193. Shultz MD, Kirby CA, Stams T, Chin DN, Blank J, Charlat O, Cheng H, Cheung A, Cong F, Feng Y, Fortin PD, Hood T, Tyagi V, Xu M, Zhang B, Shao W.. (2012) [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.. J Med Chem, 55 (3): (1127-1136). [PMID:22260203] [10.1021/jm2011222]
194. Sun H, Scott DO.. (2011) Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design.. ACS Med Chem Lett, 2 (8): (638-643). [PMID:21841964] [10.1021/ml200117z]
195. Zhang H, Tückmantel W, Eaton JB, Yuen PW, Yu LF, Bajjuri KM, Fedolak A, Wang D, Ghavami A, Caldarone B, Paterson NE, Lowe DA, Brunner D, Lukas RJ, Kozikowski AP.. (2012) Chemistry and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.. J Med Chem, 55 (2): (717-724). [PMID:22171543] [10.1021/jm201157c]
196. Wang F, Good JA, Rath O, Kaan HY, Sutcliffe OB, Mackay SP, Kozielski F.. (2012) Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.. J Med Chem, 55 (4): (1511-1525). [PMID:22248262] [10.1021/jm201195m]
197. William AD, Lee AC, Poulsen A, Goh KC, Madan B, Hart S, Tan E, Wang H, Nagaraj H, Chen D, Lee CP, Sun ET, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW.. (2012) Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.. J Med Chem, 55 (6): (2623-2640). [PMID:22339472] [10.1021/jm201454n]
198. Stec J, Huang Q, Pieroni M, Kaiser M, Fomovska A, Mui E, Witola WH, Bettis S, McLeod R, Brun R, Kozikowski AP.. (2012) Synthesis, biological evaluation, and structure-activity relationships of N-benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), Trypanosomes, and Leishmania.. J Med Chem, 55 (7): (3088-3100). [PMID:22352841] [10.1021/jm2015183]
199. McCoull W, Addie MS, Birch AM, Birtles S, Buckett LK, Butlin RJ, Bowker SS, Boyd S, Chapman S, Davies RD, Donald CS, Green CP, Jenner C, Kemmitt PD, Leach AG, Moody GC, Gutierrez PM, Newcombe NJ, Nowak T, Packer MJ, Plowright AT, Revill J, Schofield P, Sheldon C, Stokes S, Turnbull AV, Wang SJ, Whalley DP, Wood JM.. (2012) Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.. Bioorg Med Chem Lett, 22 (12): (3873-3878). [PMID:22608962] [10.1016/j.bmcl.2012.04.117]
200. Seo BI, Uchil VR, Okello M, Mishra S, Ma XH, Nishonov M, Shu Q, Chi G, Nair V.. (2011) Discovery of a Potent HIV Integrase Inhibitor that Leads to a Prodrug with Significant anti-HIV Activity.. ACS Med Chem Lett, 2 (12): (877-881). [PMID:22328963] [10.1021/ml2001246]
201. Lai MJ, Huang HL, Pan SL, Liu YM, Peng CY, Lee HY, Yeh TK, Huang PH, Teng CM, Chen CS, Chuang HY, Liou JP.. (2012) Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.. J Med Chem, 55 (8): (3777-3791). [PMID:22439863] [10.1021/jm300197a]
202. Buzard DJ, Han S, Lopez L, Kawasaki A, Moody J, Thoresen L, Ullman B, Lehmann J, Calderon I, Zhu X, Gharbaoui T, Sengupta D, Krishnan A, Gao Y, Edwards J, Barden J, Morgan M, Usmani K, Chen C, Sadeque A, Thatte J, Solomon M, Fu L, Whelan K, Liu L, Al-Shamma H, Gatlin J, Le M, Xing C, Espinola S, Jones RM.. (2012) Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease.. Bioorg Med Chem Lett, 22 (13): (4404-4409). [PMID:22633692] [10.1016/j.bmcl.2012.04.129]
203. Zhang H, Zhou L, Amblard F, Shi J, Bobeck DR, Tao S, McBrayer TR, Tharnish PM, Whitaker T, Coats SJ, Schinazi RF.. (2012) Synthesis and evaluation of novel potent HCV NS5A inhibitors.. Bioorg Med Chem Lett, 22 (14): (4864-4868). [PMID:22704887] [10.1016/j.bmcl.2012.05.039]
204. Delpire E, Baranczak A, Waterson AG, Kim K, Kett N, Morrison RD, Daniels JS, Weaver CD, Lindsley CW.. (2012) Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe.. Bioorg Med Chem Lett, 22 (14): (4532-4535). [PMID:22727639] [10.1016/j.bmcl.2012.05.126]
205. Martínez González S, Hernández AI, Varela C, Lorenzo M, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán MI, Alfonso P, García-Serelde B, Mateos G, Oyarzabal J, Rabal O, Mulero F, Gonzalez-Granda T, Link W, Fominaya J, Barbacid M, Bischoff JR, Pizcueta P, Blanco-Aparicio C, Pastor J.. (2012) Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.. Bioorg Med Chem Lett, 22 (16): (5208-5214). [PMID:22819764] [10.1016/j.bmcl.2012.06.093]
206. Rai G, Vyjayanti VN, Dorjsuren D, Simeonov A, Jadhav A, Wilson DM, Maloney DJ.. (2012) Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors.. J Med Chem, 55 (7): (3101-3112). [PMID:22455312] [10.1021/jm201537d]
207. Nagle A, Wu T, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z, Plouffe D, Lin X, Caldwell C, Ek J, Skolnik S, Liu F, Wang J, Chang J, Li C, Liu B, Hollenbeck T, Tuntland T, Isbell J, Chuan T, Alper PB, Fischli C, Brun R, Lakshminarayana SB, Rottmann M, Diagana TT, Winzeler EA, Glynne R, Tully DC, Chatterjee AK.. (2012) Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.. J Med Chem, 55 (9): (4244-4273). [PMID:22524250] [10.1021/jm300041e]
208. Miyata J, Kasahara C, Asano T, Ito S, Seki N, Kato Y, Morikawa N, Nozaki K, Nishimura K, Akamatsu H, Taguchi Y, Yamaguchi T, Abe Y, Ohkubo M, Watanabe T, Ohta M, Takeuchi M.. (2012) Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors.. Bioorg Med Chem Lett, 22 (17): (5681-5684). [PMID:22853997] [10.1016/j.bmcl.2012.06.087]
209. Tamura Y, Omori N, Kouyama N, Nishiura Y, Hayashi K, Watanabe K, Tanaka Y, Chiba T, Yukioka H, Sato H, Okuno T.. (2012) Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.. Bioorg Med Chem Lett, 22 (17): (5498-5502). [PMID:22853998] [10.1016/j.bmcl.2012.07.020]
210. Lizarzaburu M, Turcotte S, Du X, Duquette J, Fu A, Houze J, Li L, Liu J, Murakoshi M, Oda K, Okuyama R, Nara F, Reagan J, Yu M, Medina JC.. (2012) Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.. Bioorg Med Chem Lett, 22 (18): (5942-5947). [PMID:22884988] [10.1016/j.bmcl.2012.07.063]
211. N'gompaza-Diarra J, Bettayeb K, Gresh N, Meijer L, Oumata N.. (2012) Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.. Eur J Med Chem, 56 (210-216). [PMID:22982525] [10.1016/j.ejmech.2012.08.033]
212. Martínez González S, Hernández AI, Varela C, Rodríguez-Arístegui S, Lorenzo M, Rodríguez A, Rivero V, Martín JI, Saluste CG, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán M, Alfonso P, García-Serelde B, Oyarzabal J, Rabal O, Mulero F, Gonzalez-Granda T, Link W, Fominaya J, Barbacid M, Bischoff JR, Pizcueta P, Pastor J.. (2012) Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.. Bioorg Med Chem Lett, 22 (10): (3460-3466). [PMID:22520259] [10.1016/j.bmcl.2012.03.090]
213. Ikuma Y, Hochigai H, Kimura H, Nunami N, Kobayashi T, Uchiyama K, Furuta Y, Sakai M, Horiguchi M, Masui Y, Okazaki K, Sato Y, Nakahira H.. (2012) Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.. Bioorg Med Chem, 20 (19): (5864-5883). [PMID:22938786] [10.1016/j.bmc.2012.07.046]
214. Nakano H, Saito N, Parker L, Tada Y, Abe M, Tsuganezawa K, Yokoyama S, Tanaka A, Kojima H, Okabe T, Nagano T.. (2012) Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.. J Med Chem, 55 (11): (5151-5164). [PMID:22540945] [10.1021/jm3001289]
215. Suzuki T, Khan MN, Sawada H, Imai E, Itoh Y, Yamatsuta K, Tokuda N, Takeuchi J, Seko T, Nakagawa H, Miyata N.. (2012) Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.. J Med Chem, 55 (12): (5760-5773). [PMID:22642300] [10.1021/jm3002108]
216. Lowes D, Pradhan A, Iyer LV, Parman T, Gow J, Zhu F, Furimsky A, Lemoff A, Guiguemde WA, Sigal M, Clark JA, Wilson E, Tang L, Connelly MC, Derisi JL, Kyle DE, Mirsalis J, Guy RK.. (2012) Lead optimization of antimalarial propafenone analogues.. J Med Chem, 55 (13): (6087-6093). [PMID:22708838] [10.1021/jm300286a]
217. Scott JS, Gill AL, Godfrey L, Groombridge SD, Rees A, Revill J, Schofield P, Sörme P, Stocker A, Swales JG, Whittamore PR.. (2012) Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors.. Bioorg Med Chem Lett, 22 (21): (6756-6761). [PMID:23013933] [10.1016/j.bmcl.2012.08.070]
218. Su X, Halem HA, Thomas MP, Moutrille C, Culler MD, Vicker N, Potter BV.. (2012) Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.. Bioorg Med Chem, 20 (21): (6394-6402). [PMID:23040895] [10.1016/j.bmc.2012.08.056]
219. Yu LF, Tückmantel W, Eaton JB, Caldarone B, Fedolak A, Hanania T, Brunner D, Lukas RJ, Kozikowski AP.. (2012) Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.. J Med Chem, 55 (2): (812-823). [PMID:22148173] [10.1021/jm201301h]
220. Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB.. (2012) ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.. J Med Chem, 55 (1): (515-527). [PMID:22191331] [10.1021/jm2014277]
221. Yu W, Gill T, Wang L, Du Y, Ye H, Qu X, Guo JT, Cuconati A, Zhao K, Block TM, Xu X, Chang J.. (2012) Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.. J Med Chem, 55 (13): (6061-6075). [PMID:22712544] [10.1021/jm300171v]
222. Cheung YY, Yu H, Xu K, Zou B, Wu M, McManus OB, Li M, Lindsley CW, Hopkins CR.. (2012) Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.. J Med Chem, 55 (15): (6975-6979). [PMID:22793372] [10.1021/jm300700v]
223. Huber JD, Bentzien J, Boyer SJ, Burke J, De Lombaert S, Eickmeier C, Guo X, Haist JV, Hickey ER, Kaplita P, Karmazyn M, Kemper R, Kennedy CA, Kirrane T, Madwed JB, Mainolfi E, Nagaraja N, Soleymanzadeh F, Swinamer A, Eldrup AB.. (2012) Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.. J Med Chem, 55 (16): (7114-7140). [PMID:22803959] [10.1021/jm300601d]
224. Gonzalez-Lopez de Turiso F, Shin Y, Brown M, Cardozo M, Chen Y, Fong D, Hao X, He X, Henne K, Hu YL, Johnson MG, Kohn T, Lohman J, McBride HJ, McGee LR, Medina JC, Metz D, Miner K, Mohn D, Pattaropong V, Seganish J, Simard JL, Wannberg S, Whittington DA, Yu G, Cushing TD.. (2012) Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.. J Med Chem, 55 (17): (7667-7685). [PMID:22876881] [10.1021/jm300679u]
225. Asano T, Yamazaki H, Kasahara C, Kubota H, Kontani T, Harayama Y, Ohno K, Mizuhara H, Yokomoto M, Misumi K, Kinoshita T, Ohta M, Takeuchi M.. (2012) Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.. J Med Chem, 55 (17): (7772-7785). [PMID:22905713] [10.1021/jm3008008]
226. Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.. (2012) Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence.. J Med Chem, 55 (22): (9434-9445). [PMID:23009245] [10.1021/jm3005306]
227. Wong JC, Tang G, Wu X, Liang C, Zhang Z, Guo L, Peng Z, Zhang W, Lin X, Wang Z, Mei J, Chen J, Pan S, Zhang N, Liu Y, Zhou M, Feng L, Zhao W, Li S, Zhang C, Zhang M, Rong Y, Jin TG, Zhang X, Ren S, Ji Y, Zhao R, She J, Ren Y, Xu C, Chen D, Cai J, Shan S, Pan D, Ning Z, Lu X, Chen T, He Y, Chen L.. (2012) Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.. J Med Chem, 55 (20): (8903-8925). [PMID:23061376] [10.1021/jm3011838]
228. Koehler MF, Bergeron P, Blackwood E, Bowman KK, Chen YH, Deshmukh G, Ding X, Epler J, Lau K, Lee L, Liu L, Ly C, Malek S, Nonomiya J, Oeh J, Ortwine DF, Sampath D, Sideris S, Trinh L, Truong T, Wu J, Pei Z, Lyssikatos JP.. (2012) Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.. J Med Chem, 55 (24): (10958-10971). [PMID:23199076] [10.1021/jm301389h]
229. Kaila N, Huang A, Moretto A, Follows B, Janz K, Lowe M, Thomason J, Mansour TS, Hubeau C, Page K, Morgan P, Fish S, Xu X, Williams C, Saiah E.. (2012) Diazine indole acetic acids as potent, selective, and orally bioavailable antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.. J Med Chem, 55 (11): (5088-5109). [PMID:22651823] [10.1021/jm300007n]
230. Sunose M, Bell K, Ellard K, Bergamini G, Neubauer G, Werner T, Ramsden N.. (2012) Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.. Bioorg Med Chem Lett, 22 (14): (4613-4618). [PMID:22726925] [10.1016/j.bmcl.2012.05.090]
231. Gomaa MS, Bridgens CE, Illingworth NA, Veal GJ, Redfern CP, Brancale A, Armstrong JL, Simons C.. (2012) Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.. Bioorg Med Chem, 20 (14): (4201-4207). [PMID:22727372] [10.1016/j.bmc.2012.05.076]
232. Annedi SC, Maddaford SP, Ramnauth J, Renton P, Rybak T, Silverman S, Rakhit S, Mladenova G, Dove P, Andrews JS, Zhang D, Porreca F.. (2012) Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine.. Eur J Med Chem, 55 (94-107). [PMID:22840695] [10.1016/j.ejmech.2012.07.006]
233. Liu X, Chan CB, Qi Q, Xiao G, Luo HR, He X, Ye K.. (2012) Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7,8-dihydroxyflavone active in mouse models of depression.. J Med Chem, 55 (19): (8524-8537). [PMID:22984948] [10.1021/jm301099x]
234. Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, Moore AS, Kosmopoulou M, Brown N, Sheldrake PW, Bush K, Henley A, Box G, Valenti M, de Haven Brandon A, Raynaud FI, Workman P, Eccles SA, Bayliss R, Linardopoulos S, Blagg J.. (2012) Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.. J Med Chem, 55 (20): (8721-8734). [PMID:23043539] [10.1021/jm300952s]
235. Smethurst CA, Bevan N, Brooks C, Emmons A, Gough PJ, Mookherjee C, Moores K, Peace S, Philp J, Piercy V, Watson SP, Zippoli M.. (2012) In vivo activity of an azole series of CCR2 antagonists.. Bioorg Med Chem Lett, 22 (23): (7252-7255). [PMID:23079519] [10.1016/j.bmcl.2012.09.020]
236. Li H, Qin J, Dhondi P, Zhou W, Vicarel M, Bara T, Cole D, Josien H, Pissarnitski D, Zhu Z, Palani A, Aslanian R, Clader J, Czarniecki M, Greenlee W, Cohen-Williams M, Hyde L, Song L, Zhang L, Chu I, Huang X.. (2013) The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease.. Bioorg Med Chem Lett, 23 (2): (466-471). [PMID:23253441] [10.1016/j.bmcl.2012.11.055]
237. Christiansen E, Due-Hansen ME, Urban C, Grundmann M, Schmidt J, Hansen SV, Hudson BD, Zaibi M, Markussen SB, Hagesaether E, Milligan G, Cawthorne MA, Kostenis E, Kassack MU, Ulven T.. (2013) Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.. J Med Chem, 56 (3): (982-992). [PMID:23294321] [10.1021/jm301470a]
238. Shin HN, Seo SH, Choo H, Kuem G, Choi KI, Nam G.. (2013) Synthesis and antibacterial activities of new piperidine substituted (5R)-[1,2,3]triazolylmethyl and (5R)-[(4-F-[1,2,3]triazolyl)methyl] oxazolidinones.. Bioorg Med Chem Lett, 23 (5): (1193-1196). [PMID:23385213] [10.1016/j.bmcl.2013.01.033]
239. O'Reilly MC, Scott SA, Brown KA, Oguin TH, Thomas PG, Daniels JS, Morrison R, Brown HA, Lindsley CW.. (2013) Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.. J Med Chem, 56 (6): (2695-2699). [PMID:23445448] [10.1021/jm301782e]
240. Giordanetto F, Wållberg A, Knerr L, Selmi N, Ullah V, Thorstensson F, Lindelöf Å, Karlsson S, Nikitidis G, Llinas A, Wang QD, Lindqvist A, Högberg G, Lindhardt E, Åstrand A, Duker G.. (2013) Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor.. Bioorg Med Chem Lett, 23 (1): (119-124). [PMID:23200256] [10.1016/j.bmcl.2012.10.140]
241. Ting PC, Lee JF, Zorn N, Kim HM, Aslanian RG, Lin M, Smith M, Walker SS, Cook J, Van Heek M, Lachowicz J.. (2013) Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors.. Bioorg Med Chem Lett, 23 (4): (985-988). [PMID:23317570] [10.1016/j.bmcl.2012.12.040]
242. Xia G, You X, Liu L, Liu H, Wang J, Shi Y, Li P, Xiong B, Liu X, Shen J.. (2013) Design, synthesis and SAR of piperidyl-oxadiazoles as 11β-hydroxysteroid dehydrogenase 1 inhibitors.. Eur J Med Chem, 62 (1-10). [PMID:23353742] [10.1016/j.ejmech.2012.12.059]
243. Yin Y, Lin L, Ruiz C, Khan S, Cameron MD, Grant W, Pocas J, Eid N, Park H, Schröter T, Lograsso PV, Feng Y.. (2013) Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.. J Med Chem, 56 (9): (3568-3581). [PMID:23570561] [10.1021/jm400062r]
244. Amblard F, Zhang H, Zhou L, Shi J, Bobeck DR, Nettles JH, Chavre S, McBrayer TR, Tharnish P, Whitaker T, Coats SJ, Schinazi RF.. (2013) Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.. Bioorg Med Chem Lett, 23 (7): (2031-2034). [PMID:23466233] [10.1016/j.bmcl.2013.02.023]
245. Valdenaire A, Pothier J, Renneberg D, Riederer MA, Peter O, Leroy X, Gnerre C, Fretz H.. (2013) Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.. Bioorg Med Chem Lett, 23 (4): (944-948). [PMID:23324405] [10.1016/j.bmcl.2012.12.050]
246. Gardner DS, Santella JB, Duncia JV, Carter PH, Dhar TG, Wu H, Guo W, Cavallaro C, Van Kirk K, Yarde M, Briceno SW, Grafstrom RR, Liu R, Patel SR, Tebben AJ, Camac D, Khan J, Watson A, Yang G, Rose A, Foster WR, Cvijic ME, Davies P, Hynes J.. (2013) The discovery of BMS-457, a potent and selective CCR1 antagonist.. Bioorg Med Chem Lett, 23 (13): (3833-3840). [PMID:23707259] [10.1016/j.bmcl.2013.04.079]
247. Ryu BJ, Kim N, Kim JT, Koo TS, Yoo SE, Jeong SH, Kim SH, Kang NS.. (2013) Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.. Bioorg Med Chem Lett, 23 (13): (3887-3890). [PMID:23727044] [10.1016/j.bmcl.2013.04.065]
248. Woltering TJ, Wostl W, Hilpert H, Rogers-Evans M, Pinard E, Mayweg A, Göbel M, Banner DW, Benz J, Travagli M, Pollastrini M, Marconi G, Gabellieri E, Guba W, Mauser H, Andreini M, Jacobsen H, Power E, Narquizian R.. (2013) BACE1 inhibitors: a head group scan on a series of amides.. Bioorg Med Chem Lett, 23 (14): (4239-4243). [PMID:23735744] [10.1016/j.bmcl.2013.05.003]
249. Richters A, Ketzer J, Getlik M, Grütter C, Schneider R, Heuckmann JM, Heynck S, Sos ML, Gupta A, Unger A, Schultz-Fademrecht C, Thomas RK, Bauer S, Rauh D.. (2013) Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.. J Med Chem, 56 (14): (5757-5772). [PMID:23773153] [10.1021/jm4004076]
250. Gewald R, Grunwald C, Egerland U.. (2013) Discovery of triazines as potent, selective and orally active PDE4 inhibitors.. Bioorg Med Chem Lett, 23 (15): (4308-4314). [PMID:23806553] [10.1016/j.bmcl.2013.05.099]
251. Moraski GC, Markley LD, Cramer J, Hipskind PA, Boshoff H, Bailey M, Alling T, Ollinger J, Parish T, Miller MJ.. (2013) Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.. ACS Med Chem Lett, 4 (7): (675-679). [PMID:23930153] [10.1021/ml400088y]
252. Zhang HK, Yu LF, Eaton JB, Whiteaker P, Onajole OK, Hanania T, Brunner D, Lukas RJ, Kozikowski AP.. (2013) Chemistry, pharmacology, and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile. Part II.. J Med Chem, 56 (13): (5495-5504). [PMID:23734673] [10.1021/jm400510u]
253. Kwak HJ, Pyun YM, Kim JY, Pagire HS, Kim KY, Kim KR, Rhee SD, Jung WH, Song JS, Bae MA, Lee DH, Ahn JH.. (2013) Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents.. Bioorg Med Chem Lett, 23 (16): (4713-4718). [PMID:23810496] [10.1016/j.bmcl.2013.05.081]
254. Duvey G, Perry B, Le Poul E, Poli S, Bonnet B, Lambeng N, Charvin D, Donovan-Rodrigues T, Haddouk H, Gagliardi S, Rocher JP.. (2013) A novel series of metabotropic glutamate receptor 5 negative allosteric modulators based on a 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine core.. Bioorg Med Chem Lett, 23 (16): (4523-4527). [PMID:23850200] [10.1016/j.bmcl.2013.06.044]
255. Watanabe K, Kakefuda A, Yasuda M, Enjo K, Kikuchi A, Furutani T, Naritomi Y, Otsuka Y, Okada M, Ohta M.. (2013) Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.. Bioorg Med Chem, 21 (17): (5261-5270). [PMID:23845281] [10.1016/j.bmc.2013.06.025]
256. Liang J, Tsui V, Van Abbema A, Bao L, Barrett K, Beresini M, Berezhkovskiy L, Blair WS, Chang C, Driscoll J, Eigenbrot C, Ghilardi N, Gibbons P, Halladay J, Johnson A, Kohli PB, Lai Y, Liimatta M, Mantik P, Menghrajani K, Murray J, Sambrone A, Xiao Y, Shia S, Shin Y, Smith J, Sohn S, Stanley M, Ultsch M, Zhang B, Wu LC, Magnuson S.. (2013) Lead identification of novel and selective TYK2 inhibitors.. Eur J Med Chem, 67 (175-187). [PMID:23867602] [10.1016/j.ejmech.2013.03.070]
257. Manka JT, Rodriguez AL, Morrison RD, Venable DF, Cho HP, Blobaum AL, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA.. (2013) Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.. Bioorg Med Chem Lett, 23 (18): (5091-5096). [PMID:23932792] [10.1016/j.bmcl.2013.07.029]
258. Yu CW, Chang PT, Hsin LW, Chern JW.. (2013) Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.. J Med Chem, 56 (17): (6775-6791). [PMID:23905680] [10.1021/jm400564j]
259. Mirguet O, Gosmini R, Toum J, Clément CA, Barnathan M, Brusq JM, Mordaunt JE, Grimes RM, Crowe M, Pineau O, Ajakane M, Daugan A, Jeffrey P, Cutler L, Haynes AC, Smithers NN, Chung CW, Bamborough P, Uings IJ, Lewis A, Witherington J, Parr N, Prinjha RK, Nicodème E.. (2013) Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.. J Med Chem, 56 (19): (7501-7515). [PMID:24015967] [10.1021/jm401088k]
260. Valhondo M, Marco I, Martín-Fontecha M, Vázquez-Villa H, Ramos JA, Berkels R, Lauterbach T, Benhamú B, López-Rodríguez ML.. (2013) New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo.. J Med Chem, 56 (20): (7851-7861). [PMID:24050112] [10.1021/jm400766k]
261. Schoenfeld RC, Bourdet DL, Brameld KA, Chin E, de Vicente J, Fung A, Harris SF, Lee EK, Le Pogam S, Leveque V, Li J, Lui AS, Najera I, Rajyaguru S, Sangi M, Steiner S, Talamas FX, Taygerly JP, Zhao J.. (2013) Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.. J Med Chem, 56 (20): (8163-8182). [PMID:24069953] [10.1021/jm401266k]
262. Choi JY, Calvet CM, Gunatilleke SS, Ruiz C, Cameron MD, McKerrow JH, Podust LM, Roush WR.. (2013) Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.. J Med Chem, 56 (19): (7651-7668). [PMID:24079662] [10.1021/jm401067s]
263. de Lera Ruiz M, Zheng J, Berlin MY, McCormick KD, Aslanian RG, West R, Hwa J, Lachowicz J, van Heek M.. (2013) Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.. Bioorg Med Chem Lett, 23 (21): (6004-6009). [PMID:24035485] [10.1016/j.bmcl.2013.08.013]
264. Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Metz M, Harwig C, Li TS, Yang W, Bogucki D, Zhu Y, Langille J, Veale D, Ba T, Bey M, Baird I, Kaller A, Krumpak M, Leitch D, Satori M, Vocadlo K, Guay D, Nan S, Yee H, Crawford J, Chen G, Wilson T, Carpenter B, Gauthier D, Macfarland R, Mosi R, Bodart V, Wong R, Fricker S, Schols D.. (2013) Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.. J Med Chem, 56 (20): (8049-8065). [PMID:24090135] [10.1021/jm401101p]
265. Kester RF, Donnell AF, Lou Y, Remiszewski SW, Lombardo LJ, Chen S, Le NT, Lo J, Moliterni JA, Han X, Hogg JH, Liang W, Michoud C, Rupert KC, Mischke S, Le K, Weisel M, Janson CA, Lukacs CM, Fretland AJ, Hong K, Polonskaia A, Gao L, Li S, Solis DS, Aguilar D, Tardell C, Dvorozniak M, Tannu S, Lee EC, Schutt AD, Goggin B.. (2013) Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.. J Med Chem, 56 (20): (7788-7803). [PMID:24093940] [10.1021/jm400732v]
266. Richard DJ, Lena R, Bannister T, Blake N, Pierceall WE, Carlson NE, Keller CE, Koenig M, He Y, Minond D, Mishra J, Cameron M, Spicer T, Hodder P, Cardone MH.. (2013) Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.. Bioorg Med Chem, 21 (21): (6642-6649). [PMID:23993674] [10.1016/j.bmc.2013.08.017]
267. Kim HM, Smith MD, Kim JH, Caplen MA, Chan TY, McKittrick BA, Cook JA, van Heek M, Lachowicz J.. (2013) Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.. Bioorg Med Chem Lett, 23 (23): (6410-6414). [PMID:24120540] [10.1016/j.bmcl.2013.09.048]
268. Oka Y, Yabuuchi T, Oi T, Kuroda S, Fujii Y, Ohtake H, Inoue T, Wakahara S, Kimura K, Fujita K, Endo M, Taguchi K, Sekiguchi Y.. (2013) Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases.. Bioorg Med Chem, 21 (24): (7578-7583). [PMID:24262886] [10.1016/j.bmc.2013.10.042]
269. Sorna V, Theisen ER, Stephens B, Warner SL, Bearss DJ, Vankayalapati H, Sharma S.. (2013) High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.. J Med Chem, 56 (23): (9496-9508). [PMID:24237195] [10.1021/jm400870h]
270. Bürli RW, Luckhurst CA, Aziz O, Matthews KL, Yates D, Lyons KA, Beconi M, McAllister G, Breccia P, Stott AJ, Penrose SD, Wall M, Lamers M, Leonard P, Müller I, Richardson CM, Jarvis R, Stones L, Hughes S, Wishart G, Haughan AF, O'Connell C, Mead T, McNeil H, Vann J, Mangette J, Maillard M, Beaumont V, Munoz-Sanjuan I, Dominguez C.. (2013) Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.. J Med Chem, 56 (24): (9934-9954). [PMID:24261862] [10.1021/jm4011884]
271. Jones CK, Sheffler DJ, Williams R, Jadhav SB, Felts AS, Morrison RD, Niswender CM, Daniels JS, Conn PJ, Lindsley CW.. (2014) Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead.. Bioorg Med Chem Lett, 24 (4): (1067-1070). [PMID:24461352] [10.1016/j.bmcl.2014.01.013]
272. Foley TL, Rai G, Yasgar A, Daniel T, Baker HL, Attene-Ramos M, Kosa NM, Leister W, Burkart MD, Jadhav A, Simeonov A, Maloney DJ.. (2014) 4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth.. J Med Chem, 57 (3): (1063-1078). [PMID:24450337] [10.1021/jm401752p]
273. Phillips DP, Gao W, Yang Y, Zhang G, Lerario IK, Lau TL, Jiang J, Wang X, Nguyen DG, Bhat BG, Trotter C, Sullivan H, Welzel G, Landry J, Chen Y, Joseph SB, Li C, Gordon WP, Richmond W, Johnson K, Bretz A, Bursulaya B, Pan S, McNamara P, Seidel HM.. (2014) Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.. J Med Chem, 57 (8): (3263-3282). [PMID:24666203] [10.1021/jm401731q]
274. Fox BM, Sugimoto K, Iio K, Yoshida A, Zhang JK, Li K, Hao X, Labelle M, Smith ML, Rubenstein SM, Ye G, McMinn D, Jackson S, Choi R, Shan B, Ma J, Miao S, Matsui T, Ogawa N, Suzuki M, Kobayashi A, Ozeki H, Okuma C, Ishii Y, Tomimoto D, Furakawa N, Tanaka M, Matsushita M, Takahashi M, Inaba T, Sagawa S, Kayser F.. (2014) Discovery of 6-phenylpyrimido[4,5-b][1,4]oxazines as potent and selective acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents.. J Med Chem, 57 (8): (3464-3483). [PMID:24670009] [10.1021/jm500135c]
275. Kaila N, Follows B, Leung L, Thomason J, Huang A, Moretto A, Janz K, Lowe M, Mansour TS, Hubeau C, Page K, Morgan P, Fish S, Xu X, Williams C, Saiah E.. (2014) Discovery of isoquinolinone indole acetic acids as antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.. J Med Chem, 57 (4): (1299-1322). [PMID:24512187] [10.1021/jm401509e]
276. Lucas MC, Bhagirath N, Chiao E, Goldstein DM, Hermann JC, Hsu PY, Kirchner S, Kennedy-Smith JJ, Kuglstatter A, Lukacs C, Menke J, Niu L, Padilla F, Peng Y, Polonchuk L, Railkar A, Slade M, Soth M, Xu D, Yadava P, Yee C, Zhou M, Liao C.. (2014) Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.. J Med Chem, 57 (6): (2683-2691). [PMID:24520947] [10.1021/jm401982j]
277. Rai G, Joshi N, Jung JE, Liu Y, Schultz L, Yasgar A, Perry S, Diaz G, Zhang Q, Kenyon V, Jadhav A, Simeonov A, Lo EH, van Leyen K, Maloney DJ, Holman TR.. (2014) Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies.. J Med Chem, 57 (10): (4035-4048). [PMID:24684213] [10.1021/jm401915r]
278. Shi Q, Tebben A, Dyckman AJ, Li H, Liu C, Lin J, Spergel S, Burke JR, McIntyre KW, Olini GC, Strnad J, Surti N, Muckelbauer JK, Chang C, An Y, Cheng L, Ruan Q, Leftheris K, Carter PH, Tino J, De Lucca GV.. (2014) Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.. Bioorg Med Chem Lett, 24 (9): (2206-2211). [PMID:24685542] [10.1016/j.bmcl.2014.02.075]
279. Naidoo J, De Jesus-Cortes H, Huntington P, Estill S, Morlock LK, Starwalt R, Mangano TJ, Williams NS, Pieper AA, Ready JM.. (2014) Discovery of a neuroprotective chemical, (S)-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(-)-P7C3-S243], with improved druglike properties.. J Med Chem, 57 (9): (3746-3754). [PMID:24697290] [10.1021/jm401919s]
280. Sutton J, Clark DE, Higgs C, de Groot MJ, Harris NV, Taylor A, Lockey PM, Maubach K, Woodrooffe A, Davis RJ, Coleman RA, Clark KL.. (2014) From virtual to clinical: The discovery of PGN-1531, a novel antagonist of the prostanoid EP4 receptor.. Bioorg Med Chem Lett, 24 (9): (2212-2221). [PMID:24703233] [10.1016/j.bmcl.2014.02.068]
281. Manning DD, Guo C, Zhang Z, Ryan KN, Naginskaya J, Choo SH, Masih L, Earley WG, Wierschke JD, Newman AS, Brady CA, Barnes NM, Guzzo PR.. (2014) The discovery of diazepinone-based 5-HT3 receptor partial agonists.. Bioorg Med Chem Lett, 24 (11): (2578-2581). [PMID:24755431] [10.1016/j.bmcl.2014.03.074]
282. Bartolomé-Nebreda JM, Delgado F, Martín-Martín ML, Martínez-Viturro CM, Pastor J, Tong HM, Iturrino L, Macdonald GJ, Sanderson W, Megens A, Langlois X, Somers M, Vanhoof G, Conde-Ceide S.. (2014) Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.. J Med Chem, 57 (10): (4196-4212). [PMID:24758746] [10.1021/jm500073h]
283. De Savi C, Cox RJ, Warner DJ, Cook AR, Dickinson MR, McDonough A, Morrill LC, Parker B, Andrews G, Young SS, Gilmour PS, Riley R, Dearman MS.. (2014) Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.. J Med Chem, 57 (11): (4661-4676). [PMID:24785301] [10.1021/jm5001216]
284. Goswami R, Mukherjee S, Ghadiyaram C, Wohlfahrt G, Sistla RK, Nagaraj J, Satyam LK, Subbarao K, Palakurthy RK, Gopinath S, Krishnamurthy NR, Ikonen T, Moilanen A, Subramanya HS, Kallio P, Ramachandra M.. (2014) Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.. Bioorg Med Chem, 22 (12): (3187-3203). [PMID:24794746] [10.1016/j.bmc.2014.04.013]
285. Guo C, Hu M, DeOrazio RJ, Usyatinsky A, Fitzpatrick K, Zhang Z, Maeng JH, Kitchen DB, Tom S, Luche M, Khmelnitsky Y, Mhyre AJ, Guzzo PR, Liu S.. (2014) The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties.. Bioorg Med Chem, 22 (13): (3414-3422). [PMID:24842618] [10.1016/j.bmc.2014.04.036]
286. Kang S, Kim RY, Seo MJ, Lee S, Kim YM, Seo M, Seo JJ, Ko Y, Choi I, Jang J, Nam J, Park S, Kang H, Kim HJ, Kim J, Ahn S, Pethe K, Nam K, No Z, Kim J.. (2014) Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.. J Med Chem, 57 (12): (5293-5305). [PMID:24870926] [10.1021/jm5003606]
287. Dickmann LJ, VandenBrink BM, Lin YS.. (2012) In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties.. Drug Metab Dispos, 40 (7): (1263-1267). [PMID:22531045] [10.1124/dmd.112.044909]
288. Fredenhagen A, Kittelmann M, Oberer L, Kuhn A, Kühnöl J, Délémonté T, Aichholz R, Wang P, Atadja P, Shultz MD.. (2012) Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589).. Drug Metab Dispos, 40 (5): (1041-1050). [PMID:22344701] [10.1124/dmd.111.043620]
289. Strelevitz TJ, Orozco CC, Obach RS.. (2012) Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.. Drug Metab Dispos, 40 (7): (1441-1448). [PMID:22522748] [10.1124/dmd.112.045195]
290. Kamdem LK, Flockhart DA, Desta Z.. (2011) In vitro cytochrome P450-mediated metabolism of exemestane.. Drug Metab Dispos, 39 (1): (98-105). [PMID:20876785] [10.1124/dmd.110.032276]
291. Jin Y, Zollinger M, Borell H, Zimmerlin A, Patten CJ.. (2011) CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.. Drug Metab Dispos, 39 (2): (191-198). [PMID:21045201] [10.1124/dmd.110.035378]
292. Walsky RL, Obach RS, Hyland R, Kang P, Zhou S, West M, Geoghegan KF, Helal CJ, Walker GS, Goosen TC, Zientek MA.. (2012) Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.. Drug Metab Dispos, 40 (9): (1686-1697). [PMID:22645092] [10.1124/dmd.112.045302]
293. Ghosal A, Lu X, Penner N, Gao L, Ramanathan R, Chowdhury SK, Kishnani NS, Alton KB.. (2011) Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.. Drug Metab Dispos, 39 (1): (30-38). [PMID:20926621] [10.1124/dmd.110.035493]
294. Su H, Boulton DW, Barros A, Wang L, Cao K, Bonacorsi SJ, Iyer RA, Humphreys WG, Christopher LJ.. (2012) Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.. Drug Metab Dispos, 40 (7): (1345-1356). [PMID:22496391] [10.1124/dmd.112.045450]
295. Wang Z, Yang J, Kirk C, Fang Y, Alsina M, Badros A, Papadopoulos K, Wong A, Woo T, Bomba D, Li J, Infante JR.. (2013) Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.. Drug Metab Dispos, 41 (1): (230-237). [PMID:23118326] [10.1124/dmd.112.047662]
296. Bakken GV, Molden E, Knutsen K, Lunder N, Hermann M.. (2012) Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.. Drug Metab Dispos, 40 (9): (1778-1784). [PMID:22688609] [10.1124/dmd.112.045237]
297. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jørgensen M, Püschl A, Dalgaard L.. (2012) Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004.. Drug Metab Dispos, 40 (7): (1357-1365). [PMID:22496396] [10.1124/dmd.112.044610]
298. Tyndale, R R and 8 more authors.. (1991) Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.. Pharmacogenetics, [PMID:1844820]
299. Kimura, S S, Umeno, M M, Skoda, R C RC, Meyer, U A UA and Gonzalez, F J FJ.. (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.. American journal of human genetics, [PMID:2574001]
300. Gonzalez, F J FJ and 8 more authors.. (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.. Nature, (4): [PMID:3123997]
301. Gonzalez, F J FJ and 6 more authors.. (1988) Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.. Genomics, [PMID:3410476]
302. Evert, B B, Griese, E U EU and Eichelbaum, M M.. (1994) A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.. Naunyn-Schmiedeberg's archives of pharmacology, [PMID:7845481]
303. Daly, A K AK, Leathart, J B JB, London, S J SJ and Idle, J R JR.. (1995) An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.. Human genetics, [PMID:7868129]
304. Yokota, H H and 7 more authors.. (1993) Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.. Pharmacogenetics, [PMID:8287064]
305. Marez, D D and 5 more authors.. (1996) An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.. Human genetics, [PMID:8655150]
306. Masimirembwa, C C, Persson, I I, Bertilsson, L L, Hasler, J J and Ingelman-Sundberg, M M.. (1996) A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity.. British journal of clinical pharmacology, [PMID:8971426]
307. Marez, D D and 7 more authors.. (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.. Pharmacogenetics, [PMID:9241659]
308. Wang, S L SL, Lai, M D MD and Huang, J D JD.. (1999) G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese.. Drug metabolism and disposition: the biological fate of chemicals, [PMID:10064570]
309. Dunham, I I and 24 more authors.. (1999) The DNA sequence of human chromosome 22.. Nature, (2): [PMID:10591208]
310. Solus, Joseph F JF and 9 more authors.. (2004) Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.. Pharmacogenomics, [PMID:15469410]
311. Gaedigk, A A and 8 more authors.. (2005) Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.. The pharmacogenomics journal, [PMID:15768052]
312. Rowland, Paul P and 11 more authors.. (2006) Crystal structure of human cytochrome P450 2D6.. The Journal of biological chemistry, (17): [PMID:16352597]
313. Snider, Natasha T NT and 5 more authors.. (2008) The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6.. The Journal of pharmacology and experimental therapeutics, [PMID:18698000]
314. Mesaros, Clementina C, Lee, Seon Hwa SH and Blair, Ian A IA.. (2010) Analysis of epoxyeicosatrienoic acids by chiral liquid chromatography/electron capture atmospheric pressure chemical ionization mass spectrometry using [13C]-analog internal standards.. Rapid communications in mass spectrometry : RCM, (30): [PMID:20972997]
315. Badal, Simone; Gallimore, Winklet; Huang, George; Tzeng, Tzuen-Rong Jeremy and Delgoda, Rupika.. (2012) Cytotoxic and potent CYP1 inhibitors from the marine algae Cymopolia barbata.. Organic and medicinal chemistry letters, (11): [PMID:22686946]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

货号 (SKU)	包装规格	是否现货
Ab098589-10μl	10μl	现货
Ab098589-50μl	50μL	现货
Ab098589-100μl	100μL	期货
Ab098589-1ml	1ml	期货

Recombinant CYP2D6 Antibody

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

应用

质检证书（CoA,COO,BSE/TSE 和分析图谱)

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

Recombinant CYP2D6 Antibody

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

应用

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器